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ABSTRACT 
 
 
Proinsulin Trafficking through the Secretory Pathway 
 
By 
 
 Gautam Rajpal 
 
Chair: Peter Arvan 
 
Proinsulin, the insulin precursor protein, is synthesized in the Endoplasmic 
Reticulum (ER) of pancreatic beta cells, where it folds to the native state, 
involving the formation of three evolutionarily conserved disulfide bonds.  Once 
folded, proinsulin exits the ER, traverses the secretory pathway to the trans-Golgi 
Network (TGN) and into budding secretory granules.  Proinsulin is then 
processed by endopeptidases that excise the connecting C-peptide that links the 
 xi 
 
B- and A-chains, leading to the creation of mature, two-chain insulin.  Upon 
secretion to the bloodstream, insulin binds to cell surface insulin receptors on 
target tissues, resulting in the activation of signaling cascades that promote 
metabolic homeostasis.  This thesis aims to look at two distinct aspects of the 
proinsulin maturation process.  In the first part of my thesis work, I have designed 
a proinsulin with a shortened linker peptide with the intent to create a 
bioengineered protein that acts as a single-chain insulin (SCI), i.e., without a 
requirement for cleavage by endopeptidases.  SCIs expressed via gene therapy 
have been found to be effective in reversing diabetes in rodent models, obviating 
the need for exogenous insulin injection.  However, to date, very little structure-
function analysis of SCIs has been performed.  In Chapter 2, I have examined 
the structural features of the linker peptide that would allow for mammalian 
expression, secretion, and bioactivity of SCIs for development into future 
diabetes therapeutics.  In the second part of my thesis work, I have been 
attempting to identify the ER oxidoreductase(s) that promote(s) formation of the 
three disulfide bonds of proinsulin, which heretofore are unknown.  In Chapter 3, 
I present results that point to two key members of the family of PDI-like ER 
oxidoreductases: Protein Disulfide Isomerase itself, and Endoplasmic Reticulum 
protein 72 (ERp72), which may both play critical, yet opposing, roles in this 
 xii 
 
process.  As the misfolding of proinsulin is implicated in the progression of 
various forms of diabetes, understanding the key factors that control the balance 
of proinsulin folding and misfolding (by regulating proinsulin disulfide bond 
formation) could also provide potential benefit for designing therapies that 
increase insulin production.  
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Chapter 1    INTRODUCTION 
 
Like cancer, diabetes mellitus is a disease of various etiologies, with a final 
common pathology leading to increased blood glucose levels [35, 68, 87, 110].  
Diabetes resulting from autoimmune attack on pancreatic beta cells (leading to 
elimination of the insulin producing cells) is now known as Type IA diabetes [87].  
Diabetes in persons with decreased tissue sensitivity to insulin, resulting in 
elevated blood glucose, is known as Type II diabetes (Interestingly, this also 
results in eventual loss of pancreatic beta cells, but  triggered by non-immune 
insults) [68].  Type II diabetes is polygenic, and increasing subgroups of 
individuals are now recognized with mutations in a variety of critical genes 
impacting on insulin secretion and beta cell physiology (Including the insulin gene 
itself)[109, 120, 170].  Some monogenic forms of the disease begin in the 
neonatal period and can be confused for Type 1A diabetes but are now 
considered Type 1B (non-autoimmune) diabetes [35, 96, 110]. Gestational 
diabetes, which occurs in mothers during the third trimester of pregnancy, is yet 
another form of diabetes commonly associated with the development of type II 
diabetes in later life[145].  
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All forms of diabetes, in one form or another, involve the insufficiency or inaction 
of insulin.  In humans, insulin is formed as a precursor known as preproinsulin, a 
120 amino acid molecule containing a 24 amino acid signal peptide sequence. 
The signal peptide binds to a signal recognition particle, which brings 
preproinsulin to the Endoplasmic Reticulum (ER) [97].  During translation on the 
ribosomes of the rough ER, the signal peptide is recognized and translocated, via  
the Sec61 channel, across the ER membrane into the ER lumen for folding [10, 
55]. The continued translation and translocation into the ER (so-called co-
translational translocation) occur simultaneously.  In this process, the signal 
peptide is cleaved by signal peptidase to form proinsulin, which interacts with 
enzymes and chaperones within the ER lumen [55].  Proinsulin then begins to 
fold, forming three evolutionarily conserved disulfide bonds, allowing proinsulin to 
assume its native three dimensional conformation [98].  After achieving its native 
conformation, proinsulin exits the ER and transits to the Golgi complex, where it 
enters the Trans Golgi Network (TGN) and is packaged into immature secretory 
granules [10].  As these granules begin to mature, an acidification process 
(driven via the action of an ATP driven proton pump) allows for enzymatic activity 
of endoproteases that cleave residues 31-65, a region otherwise known as the C-
peptide [10, 45, 55].  These enzymes include proprotein convertases PC1 and 
PC2, and carboxypeptidase E.  The endopeptidase PC1 recognize cleaves the 
dibasic motif -RR within proinsulin (near the B-chain) and endopeptidase PC2 
cleaves the dibasic motif -KR (near the A-chain); these dibasic residues are then 
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removed by the action of carboxypeptidase E [45].  Excision of this 31 amino acid 
C-peptide leaves a two-chain structure, (B- and A-chains, respectively) linked by 
the two of the three disulfide bonds, resulting in the formation of the mature 
molecule known as insulin.  Once endoptoteolytically processed, insulin 
hexamers proceed to form higher-order multimers, and ultimately crystallize in 
the secretory granules in the presence of zinc and calcium [10, 55].  It is 
estimated a single insulin secretory granule can contain up to a million molecules 
of insulin[10].  Insulin remains stored in these granules until activation of nutrient 
mediated signaling cascades, whereupon granules fuse with the plasma 
membrane by exocytosis, releasing insulin into the extracellular space.  The 
insulin crystals immediately dissolve into monomeric (active) forms (each B-
chain/A-chain pair is a monomer), circulating in the bloodstream with insulin 
exerting its effects on target tissues by binding and activating insulin receptors 
[55].  
Binding of insulin causes dimeric insulin receptors to trans-phosphorylate, via an 
internal kinase domain, on tyrosines found within the cytoplasmic domain of the 
insulin receptor  [135].  This promotes the recruitment of the IRS (Insulin 
Receptor Substrate) adapter proteins, which further recruit factors that activate 
the insulin signaling cascade [135].  Eventually, such signaling in fat and muscle 
cells results in the translocation of the GLUT4 glucose transporter from the 
perinuclear membranes to the plasma membrane, which allows for regulated 
glucose entry into these cells [135].  
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In Type IA diabetes, autoimmune destruction of pancreatic beta cells leaves the 
body with little or no insulin and C-peptide.  Existing treatment therefore requires 
daily injections of exogenous, recombinantly-produced insulin.  Currently, 
recombinant insulin is manufactured in two ways.  Humulin ® and its analog 
Humalog ®, produced by Eli Lilly and Company, are formed by separately 
expressing the cDNA sequences of the insulin B- and A- chains in E. coli [2].  
The chains are then combined in a reaction under conditions that allow for the 
formation of appropriate disulfide linkages between the two chains.  Alternatively, 
insulin produced by Novo-Nordisk is created in yeast, where a single chain 
insulin precursor is synthesized and recombinant secreted protein is 
subsequently endoproteolytically cleaved in vitro [1].  
Mutations have been engineered into insulin that affect the properties of the 
injected product, in particular with regards to its half-life in the bloodstream.  
According to a 2005 New England Journal of Medicine article,” the proper use of 
insulin analogs allows people with diabetes greater flexibility in the timing of 
meals, snacks, and exercise, which in turn enhances their ability to lead normal 
lives” [52].  ‘Lispro ®’, the first insulin analog sold, is a fast acting insulin in which 
the lysine and proinsulin residues on the C-terminal end of the B-chain are 
placed in reverse order [56].  The residue swap inhibits formation of insulin 
dimers and hexamers, which allows for more rapid absorption and bioavailability 
of monomeric insulin.  Lispro® is able to interact with the insulin receptor at 
similar binding affinities to that of native insulin.  In the Novo-Nordisk product 
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known as “Aspart ®”, the same insulin-B28 residue that is normally a proline is 
mutated to aspartic acid [72].  This too prevents hexamer formation and allows 
for a more rapidly absorbed, faster-acting insulin.  On the other hand, Glargine ®  
insulin and Detemir insulin (trade names: Lantus ®  and Levemir ®, respectively) 
are examples of bioactive insulin analogs that are unusually long-lasting [112, 
160].  These analogs are able to survive in the bloodstream much longer than 
normal insulin by shifting their isolelectric points (the pH at which the overall 
molecule carries no net electrical charge).  In the case of Glargine ®  insulin, this 
was done by adding two positively charged arginine residues to the C-terminus of 
the B-chain (the acid-sensitive asparagine at position 21 in the A-chain to glycine 
was also changed in order to avoid deamination and dimerization) [160].  Detemir  
on the other hand was modified so that it could be fatty acylated and thus carried 
for extended periods in the circulation bound to serum albumin[112].   
In Type II diabetes, muscle and fat tissues, the main targets of insulin action, 
tend to lose their sensitivity to insulin so that the signaling response activated 
upon insulin binding is attenuated [68, 135].  As a result, pancreatic beta cells 
must produce more insulin to compensate for the insulin insensitivity [139].  Over 
time, however, if the insulin insensitivity is not improved (or worsens still), then 
beta cells may eventually fail to keep up with insulin production as they become 
overwhelmed by glucose [18, 24, 164].  Under conditions of glucotoxicity, beta 
cells are predisposed to undergo apoptosis [165]. The mechanism of this 
pathology is unclear and currently under investigation in many labs.  Among the 
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popular theories, a favored view is that oxidative stress and ER stress may lead 
to beta cell failure [33, 54, 116, 134, 139, 144]. Oxidative stress (which can also 
be triggered by ER Stress) occurs when there is an accumulation of reactive 
oxygen species (ROS), which includes superoxide, hydrogen peroxide, hydroxyl 
radical, and peroxynitrite molecules [33, 134, 144].  ROS are normally 
neutralized by antioxidant gene products (enzymes) that can be expressed in 
cells[144].  Inexplicably, pancreatic beta cells that produce massive amounts of 
oxidized proinsulin have low levels of expression of antioxidant enzymes, which 
limits their ability to deal with such insults [89].  ROS production that remains 
unquenched can cause damage to cellular components and even lead to 
apoptosis [105].  Evidence for oxidative stress as a potential culprit for pancreatic 
beta cell failures does exist, both from rodent models and human data.  Autopsy 
of diabetic islets suggested an increase in ROS, while tissue damage has been 
found to be increased in the pancreas of diabetic subjects when subject to 
oxidative stress [18, 134].  
 ER stress occurs when misfolded or unfolded proteins accumulate in the ER 
[54]. Three ER stress sensor proteins in the ER membrane: Ire1, PERK, and 
ATF6, activate the unfolded protein response (UPR), which respectively serves 
three primary functions within the cell: inhibition of general protein translation, 
increased protein folding capacity of the ER, and degradation of misfolded 
proteins in the ER [113].  Initially, UPR activation is an adaptive response to 
reduce ER stress and can serve to improve cell function [11, 113, 140].  In 
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contrast, prolonged UPR leads to apoptosis via expression of the transcription 
factor CHOP, among others [54, 147].  ER stress and UPR induction are both 
increased in islets of human diabetic patients and animal models of diabetes [46, 
54, 61, 82, 104].  CHOP in particular may have an important role to play in 
mediating ER stress-induced beta cell failure, since CHOP deletion ameliorates 
the diabetic phenotype in genetic and diet-induced models of diabetes [147].   
The source of potential ER Stress in pancreatic beta cells may be linked to 
proinsulin folding [96-98].  To be precise, proinsulin misfolding may elicit a toxic 
ER Stress response, supported by findings in the Akita mouse, which expresses 
a terminally misfolded proinsulin — the expression of which is ultimately 
associated with a loss of pancreatic beta cells [161].  Recent studies have 
revealed that additional coding sequence mutations in the INS gene itself — one 
of the causes of monogenic Type 1B diabetes in humans— also leads to the 
demise of pancreatic beta cells [96, 110].  While some of these mutations 
specifically alter the key cysteine residues involved in the formation of 
proinsulin’s three disulfide bonds, other mutations appear to indirectly impact on 
the ability of proinsulin to create its disulfide bonds and thus to form its native 
conformation.  This even includes mutations in the preproinsulin signal peptide 
sequence which can result in aberrant proinsulin oxidation [97, 106]. Thus, by 
affecting the cotranslational transolocation of (pre)proinsulin, this appears to 
impact on its oxidation. These mutations are also purported to exhibit dominant-
 8 
 
negative effects, perturbing the folding of “bystander” wild-type proinsulin, further 
exacerbating the toxic phenotype.  
In people with Type II diabetes, elevated blood lipid and glucose levels can also 
become toxic to beta cells [165].  Current treatment has focused on increasing 
the sensitivity of insulin target tissues as well increasing the amount of insulin 
secreted from pancreatic beta cells [120].  However clinical data indicate that 
treatments designed to promote increased insulin synthesis and secretion 
ultimately lead to more rapid progression of the disease with earlier dependence 
upon exogenous insulin injection (e.g., the DREAM study) [3, 83].  The data 
suggest that accelerated loss of beta cells may occur by forcing diabetic beta 
cells to produce more proinsulin than they are genetically programmed to handle.  
At the present time, no pharmacological treatments are currently commercially 
available that are designed to directly reduce ER Stress or failure of pancreatic 
beta cells.  
My Ph.D. thesis research highlights attempts to look at potential treatments for 
both Type I and Type II diabetes.  For my first project, dealing with Single-Chain 
Insulins (SCIs), I created insulin analogs that might be utilized in a gene therapy 
approach, obviating the need for daily insulin injections.  These analogs do not 
require endoproteolytic processing for insulin bioactivity.  To date, no SCI has 
come to market, and only a few studies have examined the features that would 
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be necessary to make a bioactive SCI.  Such a treatment was shown to be 
successful in “curing” diabetes in streptozotocin-treated diabetic rodents [84].   
My second project, which represents the larger portion of my thesis work, was 
designed to understand more about proinsulin folding and its link to insulin 
production.  Specifically, I attempted to identify ER oxidoreductase activities that 
help or hinder proinsulin disulfide bond formation in the ER.  If proinsulin 
misfolding is a source of ER Stress in pancreatic beta cells, then understanding 
the mechanism of folding, and using that understanding to potentially improve 
folding, would be of the upmost importance.  Although each project has 
therapeutic aims and implications, both were set out with the intention of 
understanding basic mechanisms in proinsulin biology. 
Note: each chapter will begin with an introduction that contains a more specific 
background of the field related to that chapter.   
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Figure 1-1. Crystal structure of insulin.  
B-chain in dark. A-chain in light. Disulfide bonds shown in medium. For 
proinsulin, the C-peptide region is located between end of the B-chain (B30) and 
the beginning of the A-chain (A1).  
 
Source: Hidehiko Nakano. http://www.sccj.net/CSSJ/jcs/v4n1/a1/text.html. 
 
 
 
 11 
 
 
Chapter 2  SINGLE-CHAIN INSULINS AS RECEPTOR AGONISTS 
 
Gautam Rajpal, Ming Liu, Yi Zhang, and Peter Arvan. Molecular Endocrinology 
May 1, 2009 vol. 23 no. 5 679-688. 
 
2.1 Abstract 
 
Single-chain insulins (SCIs) are single polypeptide chains in which the insulin B-
chain links contiguously with the insulin A-chain via an uncleaved connecting 
peptide.  While direct linkage of insulin B- and A-chains produces SCIs with little 
insulin receptor binding, biologists have been interested in bioengineering linker 
peptides that form a flexible reverse turn, allowing SCIs to activate insulin 
receptors.  In this report, I have investigated a series of cDNAs intended to 
explore the significance of linker length, cleavability, and the impact of certain 
site-dependent residues for the expression and bioactivity of recombinant SCIs 
on insulin receptors.  SCI concentration is readily measured by 
radioimmunoassay with a (proinsulin + insulin)-specific polyclonal antibody.  
While dibasic flanking residues may result in potential endoproteolytic 
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susceptibility, a linker with -Gln-Arg- flanking sequences resisted cleavage even 
in secretory granules, ensuring single-chain behavior.  Effective SCIs exhibit 
favorable and specific binding with insulin receptors.  SCIs with linkers bearing 
an Arg residue immediately preceding the A-chain were most bioactive, although 
efficient receptor interaction was inhibited as SCI linker length increased, 
approaching that observed for proinsulin.  SCIs activate downstream metabolic 
signaling — stimulating glucose uptake into adipocytes and suppressing 
gluconeogenic enzyme biosynthesis in hepatocytes — with only limited cross-
reactivity on IGF1 receptors.  SCIs might theoretically have utility either in 
immunotherapy or gene therapy in insulin-deficient diabetes.   
 
Significance: Currently there are very few publications on the efficacy of SCIs 
[60, 84], and none on the properties that confer biological activity. The 
significance is that such agents may have potential use in the treatment of 
diabetes mellitus.  
 
2.2  Introduction 
 
Absolute or relative insulin deficiency is a major factor underlying the inability of 
diabetic patients to maintain normal blood glucose levels.  For both type 1 and 
type 2 diabetic patients, injection of purified insulin is a major therapy although 
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alternative products [34] and routes, such as insulin inhalation [131], have been 
considered.  In recent years, insulin gene therapy (especially for type 1 diabetes 
caused by autoimmune-mediated destruction of pancreatic beta cells) has also 
been in development, with the intention that hyperglycemia could trigger 
production and secretion of bioactive insulin from genetically-targeted non-beta 
cells.   
In beta cells, insulin is derived from the proinsulin precursor [62, 78] which is 
endoproteolytically processed via the combined actions of PC1, PC2, and 
carboxypeptidase E [174].  These enzymes are optimally active within the 
intraluminal environment of secretory granules, but they are generally not 
expressed in cells other than neuroendocrine cells [25].  However, using 
biotechnology, expression of modified insulin cDNAs in non-beta cells may allow 
for the synthesis and secretion of products with strong specificity for insulin 
receptors [155].  For example, mutagenesis to alter endoproteolytic processing 
sites in proinsulin has been employed to enhance cleavability in non-beta cells.  
Nevertheless, endoproteolytic processing efficiency of such constructs remains 
variable [8, 143], limiting production of bioactive insulin from heterologous cells.   
As an alternative, single-chain insulin (SCI) constructs [59] may have utility.  
SCIs require no endoproteolytic processing for activation.  Lee at al. described 
an SCI bearing a heptameric peptide linking insulin B- and A-chains with 20 - 
30% binding efficiency to insulin receptors compared to authentic insulin; this 
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does not preclude favorable in vivo effects to lower blood glucose in diabetic 
rodent models [85] and potentially, in humans [130].  Lee at al. inserted this 
construct into a plasmid hepatocyte-specific Liver-type pyruvate kinase (LPK) 
promoter.  It has been shown that glucose-induced transcription of the LPK gene 
is mediated by a carbohydrate response elements (ChRE) located within its 
promoter  [167].  The authors used this to their advantage, selecting a promoter 
that would be activated by glucose, thereby mimicking the beta cell response, to 
release insulin on demand.  Using a retrovirus to deliver this construct into the 
hepatocytes of mice, the authors were able to lower blood glucose levels in non-
obsese diabetic (NOD) mice (which undergo autoimmune destruction of beta 
cells) as well as in streptozotocin-induced diabetic rodents (streptozotocin is a 
drug selectively toxic to pancreatic beta cells).  The authors demonstrated 
remission of diabetes over a fifteen week observation period.  Thus, this single 
chain insulin, despite not being processed nor displaying the full bioactivity of 
insulin, was nevertheless an effective treatment in treating diabetes, without the 
need for insulin injections.  However, Lee et al did not provide information on the 
development of the SCI and why certain attributes (linker length, amino acid 
content) were chosen over other possibilities. 
The apparent bioactivity of this heptameric peptide linked SCI calls attention to 
the function of the C-Peptide.  The mammalian proinsulin C-peptide is typically 
35 amino acids in length, including the two dibasic motifs found at the ends of the 
linker, and contains 4 or 5 acidic residues, with at most a single basic residue in 
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a limited number of species [149].  The conservation in length is fairly consistent 
across species, including invertebrates such as mollusks and arthropods. [80, 
146, 149].  Work done by Liu et al have shown that reducing the length of the C-
peptide to less than five amino acids residues results in proinsulin misfolding with 
improper disulfide bonds [100]. However, above five amino acids, the folding 
fidelity of proinsulin appears to remain intact.  The requirement above five amino 
acids may also involve additional evolutionary pressures beyond folding.  
Approximately 95% of proinsulin in secretory granules is converted into mature 
insulin.  In order to maintain this high efficiency, the C-peptide needs to display 
characteristics that allow its efficient endoproteolytic excision to occur.  For 
instance, at least 8 or 9 residues (6 upstream, 2- 3 downstream) at the two 
proinsulin processing sites must fit into the catalytic grooves on the convertases 
for efficient excision [95, 149] .  The C-peptide must also allow for proper 
hexamerization of proinsulin that occurs during its export from the ER to the 
TGN.  Furthermore, the C-peptide is purported to display some biological 
activity(ies) on its own, which may impose a further evolutionary constraint [51].  
Interestingly, a subset of evolutionarily-related proteins to insulin, the Insulin-like 
Growth Factors IGF-1 and IGF-2, exhibit single chain insulin-like characteristics 
[90]. The IGFs share similarities in both structure and function, and work through 
an IGF1 receptor with functional homology to the insulin receptor.  Like proinsulin 
and insulin, they posses three disulfide bonds, connecting regions that 
correspond to the “B” and “A” chains.  However, unlike insulin, the C-peptide 
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region is never excised and thus remains intact.  Furthermore, the C-peptides of 
IGFs are much shorter than the C-peptide found in insulin, and they appear  to 
contribute to IGF1 receptor binding [19].  This is an important distinction as some 
Single-Chain Insulins may exhibit greater crossover agonist activity on IGF1 
receptors than does two-chain insulin.  If the intention is to use the SCI in gene 
therapy for treatment in diabetes, then minimizing crossover bioactivity with the 
IGF-1 receptors is of the upmost importance as activation of growth signaling 
cascades can lead to undesirable clinical side effects [42].   
In this work, I have endeavored to further characterize sequences comprising the 
flexible linker peptide that might improve the biological properties of SCIs.  I also 
tested SCIs for crossover bioactivity on IGF-1 receptors.  From my studies, a list 
has been generated of suitable SCIs that exhibit comparable bioactivity to that 
studied by Lee et al.[84], including an SCI with no potential to be cleaved by any 
known endoprotease of the secretory pathway.  
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2.3 Results 
 
Measuring SCI levels  
A list of SCI constructs engineered for this study, varying only by their linker 
sequences, is summarized in Table 2-1.  My screening strategy for this study has 
been to 1) measure the amount of each recombinant SCI secreted from 
transiently transfected 239T cells; 2) screen for the potential for endoproteolytic 
cleavage of recombinant SCIs that would inadvertently convert them from single-
chain to two-chain insulins; and 3) compare recombinant SCIs secreted from 
293T cells for insulin receptor interaction using a screening assay that obviates 
the need for protein purification.   
To normalize the amounts of secreted SCI protein, I exploited a 
radioimmunoassay (RIA) kit (based upon a polyclonal antibody intended to detect 
rat pro/insulin, but with extensive cross-reaction to proinsulin+insulin of all 
species) in order to measure the relative concentrations of secreted recombinant 
SCIs.  Using this assay in transfected 293T cells, all constructs tested (Table 2-1) 
yielded in the range of 20 - 200 ng of recombinant SCI protein secreted per well.  
The stock concentrations of each SCI were then diluted to equalize their 
concentrations in subsequent bioassays.  I verified the validity of the RIA 
measurements for several SCIs by continuous metabolic labeling of transfected 
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293T cells for 24 h with 35S-cysteine at a fixed specific radioactivity in complete 
culture medium, to approach steady state labeling.  Because each construct has 
the same number of Cys residues (six) per SCI molecule, I could directly 
examine the abundance in these SCIs, and in parallel, quantify SCI levels by 
RIA.  Quantitative recovery of secreted SCIs was achieved by an 
immunoprecipitation protocol with a vast excess of anti-insulin antibody (see 
Methods), before tris-tricine-urea-SDS-PAGE and autoradiography.  In Fig. 2-1, 
small differences in band mobilities for the distinct constructs can be explained 
by the presence of 4, 7, 8, and 9 amino acid linker sequences (consistent with 
previous reports [100]).  Importantly, because of precise identity of the insulin B-
chain and A-chain sequences in all constructs, immunoreactivity of the SCIs 
appeared proportionate to the chemical mass of SCI protein detected after 
steady-state labeling (Fig. 2-1).   
 
Stringent Assay of Cleavability   
When considering potential future therapeutic uses, I wished to generate a 
recombinant SCI that was "effectively uncleavable", yielding a single product with 
defined biological characteristics.  However, most SCI sequences reported to 
date have one or two sets of flanking dibasic amino acids contiguous with either 
the B- or A-chain [59, 85].  Many of the SCIs produced also have dibasic 
residues within the linker sequence (Table 2-1), with at least theoretical potential 
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for cleavage.  To directly test cleavability, I exploited the subtilisin-like 
proteinases found in secretory granules [148]; specifically, those found in 
AtT20/PC2 cells that do not synthesize proinsulin yet express PC1 and PC2 and 
possess a microenvironment conducive to endoproteolytic processing of peptide 
hormone precursors [25].  I therefore transfected AtT20/PC2 cells with cDNAs 
encoding SCIs bearing the following linkers: -QRGGGGGQR- (Table 2-1 line 27),  
-GGGPGKR- (Table 2-1 line 15), -RRGGGGGKR- (Table 2-1 line 20), -
RRYLGGGGGGGDVKR- (Table 2-1 line 34), -C-peptide- (ie, proinsulin, Table 2-
1 line 36), or Direct Linkage of Thr(B30)-G(A1) with no potential cleavage  site 
between the chains (Table 2-1 line 2).  The cells were pulse-labeled with 35S-
amino acids and after the first 3 h chase, two further sequential 30 min chase 
incubations were collected for analysis of media under unstimulated and 
secretagogue-stimulated conditions, respectively.  Anti-insulin 
immunoprecipitates from media were examined by nonreducing tris-tricine-urea 
SDS-PAGE and fluorography in order to observe band mobility, which reflects 
both disulfide bonding as well as potential endoproteolysis [63].  Nearly all bands 
immunoprecipitable with anti-insulin exhibited stimulated release upon 
secretagogue addition (Fig. 2-2), indicating that these peptides had entered 
secretory granules, which maintain an endoproteolytically active internal 
environment.  As expected, the construct with a -C-peptide- linker (ie, proinsulin, 
9.5 kD) was in part cleaved, resulting in authentic insulin production (5.9 kD).  
With this insulin band as a 'standard', it was apparent that SCIs with linkers -
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RRGGGGGKR- or  -RRYLGGGGGGGDVKR-, respectively, were also 
endoproteolytically processed to insulin (Fig. 2-2).  As a control, the direct linkage 
construct (lacking any processing site between the chains) was uncleavable.  
However, this SCI differs from others in that the band mobility under nonreducing 
conditions is aberrantly slow, reflecting quantitatively mispaired disulfide bonds 
despite a molecular mass identical to that of authentic insulin [100].  The SCI with 
linker -GGGPGKR-, used previously for gene therapy in rodent diabetes [85], 
showed an as-yet uncharacterized cleavage in AtT20/PC2 cells.  By contrast, the 
SCI with a -QRGGGGGQR- linker appeared uncleavable (Fig. 2-2).   
A different RIA that measures only processed human insulin provided an indirect 
but simpler alternative method to confirm that the SCI bearing a nonapeptide 
linker with QR flanking sequences remains intact as a SCI even under these 
protease-rich conditions.  By comparing the results from an RIA to detect 
(proinsulin+insulin) to those of an RIA detecting only human insulin, I examined 
AtT20/PC2 cells transfected to express an SCI bearing a linker with a set of two 
flanking dibasic sites (Table 2-1 line 19), or a linker with only one dibasic site at 
the A-chain junction (Table 2-1 line 15), or the -QRGGGGGQR- linker lacking 
any dibasic sites (Table 2-1 line 27).  The ratio of total (proinsulin+insulin)-
specific immunoreactivity [ie, total expression] to human insulin-specific 
immunoreactivity [ie, processed protein] for the SCI with a bilateral set of flanking 
dibasic sites was 1.94 : 1, indicating significant cleavage.  The ratio for the SCI 
with only one dibasic site at the A-chain junction was 2.65 : 1, and for that with no 
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dibasic sites the ratio was 20.8 : 1.  These data indicate progressive resistance to 
cleavage and support the contention that an SCI with a -QRGGGGGQR- linker is 
likely to remain intact as a single-chain protein, even in an endoprotease-rich 
microenvironment.   
 
Screening of SCI interaction with cell surface insulin receptors  
Metabolic responsiveness in insulin-sensitive tissues in the body has long been 
reported to be reflected by efficiency of insulin extraction from the bloodstream 
[14, 50, 108] or from the perfusate of isolated organs [150] or the medium 
bathing cultured cells — in which insulin extraction is linked to (and preceded by) 
binding to cell surface insulin receptors.  Indeed the amount of insulin extracted 
from the medium and entering intracellular trafficking pathways in cultured cells 
(eg., hepatocytes) is proportional to the amount that binds to cell surface insulin 
receptors [92].  With these observations in mind, I devised an assay in which the 
ability of various recombinant SCIs, secreted from 293T cells, could be screened 
for interaction with insulin receptors by virtue of their extraction from media 
bathing Chinese Hamster Ovary cells stably overexpressing human insulin 
receptors (CHO-IR cells).  Following overnight serum starvation, I exposed CHO-
IR cells to recombinant SCIs that had been secreted from 293T cells and diluted 
to a concentration of 5 ng/mL in fresh media.  The diluted SCIs were placed upon 
confluent cells and the incubations cooled to 4°C for 6 h to allow for SCI 
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extraction from the media via iteraction with cell surface insulin receptors.  
Extraction was directly measurable by loss of SCIs from the media was directly 
measured (by RIA) – compared to that observed for chemically purified human 
insulin (this positive control set to 100%).  The technical simplicity of the assay 
resulted in a highly reproducible means to order the relative extraction efficiency 
between different SCI constructs.   Moreover, our positive control (human insulin) 
as well as our “negative” controls (Direct Linkage of B- to A-chain, Table 2-1  
lines 1 and 2) yielded results reflecting their status as being the strongest and 
weakest ligands, respectively (although there was inter-assay variability with 
regards to nonspecific background [93] as measured by constructs known to 
have little specific receptor interaction [29]).  I therefore used this extraction 
assay as a screening tool to suggest features for effective design of recombinant 
SCI proteins that were expressed and secreted from transiently transfected 293T 
cells.   
An SCI with a nonapeptide linker (-RRYPGDVKR-), which includes residues that 
allow bending the linker into a reverse turn, has been described to exhibit 50% of 
the insulin receptor binding efficiency of that observed for two-chain insulin [22] 
yet significantly higher than that of proinsulin [59].  I used this linker as my basis 
for designing further constructs. I observed that substitution of the central Pro by 
Leu had no adverse (and indeed slightly beneficial) effects on secretory recovery 
of the recombinant SCI, as well its extraction by CHO-IR cells (Table 2-1, lines 
18 and 19).   
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I then varied the c-peptide length to determine the ability of the SCI to bind to the 
receptor.  It was my hypothesis that an excessive linker length might sterically 
interfere with insulin receptor interaction while,  on the other hand, a minimum 
linker length may be required to allow flexibility for efficient conformational 
adaptation of SCI contact sites with the receptor.  From the data in Fig. 2-3A, 
both points seemed apparent.  At one end of the spectrum, I expressed SCIs 
bearing a 15-mer linker (Table 2-1 line 34) and a 20-mer linker (Table 2-1 line 35) 
that exhibited progressive decreases in extraction by CHO-IR cells, which fell 
further upon expansion of the linker to include the full proinsulin C-peptide (Fig. 
2-3A).  These data are consistent with steric hindrance to insulin receptor binding 
[59, 74].  At the other end of the spectrum, none of our recombinant SCIs with a 
linker size that was < 6 residues showed important extraction by CHO-IR cells 
(including linkers -MGGM-, -GKR-, -KR-, or our direct linkage negative control, 
Fig. 3A and see lines 1-11 of Table 2-1).  Some of the inability to interact with 
insulin receptors may include a degree of misfolding of recombinant SCIs with 
short linkers [100] as well as the inability of SCIs with tightly tethered chains to 
undergo the motion needed to fit against the insulin receptor [29, 115].  We did 
observe binding to the insulin receptor with as few as five amino acids, with the 
linker-RRGKR-. However,  this linker is a predicted furin cleavage site and is in 
fact a miniproinsulin (ie, not an SCI) that is quantitatively converted in Golgi 
complex of 293T cells to two-chain insulin (see Table 2-1, and data not shown).  
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Thus, the minimum linker length for optimal binding appeared to be seven amino 
acids (Table 2-1 line 15).  
Next, because an SCI bearing an -RRYPGDVKR- linker is efficiently extracted by 
CHO-IR cells (Fig. 2-3B), as is the SCI bearing the published linker sequence -
GGGPGKR- [85], I became intrigued by the dibasic site found at the linker-A-
chain junction, which has also been reported in another newly-described insulin 
receptor-binding SCI [59].  To test the significance of flanking dibasic residues in 
the linker sequence, the SCI from Table 1 line 19 was further mutagenized to 
either convert the amino terminal end of the linker from RR to GG (Table 2-1 line 
22) or the carboxyl-terminal end from KR to GG (Table 2-1 line 21).  While loss of 
the amino terminal RR still resulted in excellent extraction by CHO-IR cells, loss 
of the carboxyl-terminal KR resulted in a dramatic decrease in extraction 
efficiency (Fig. 2-3B).  Substitution at the carboxyl terminal end of the SCI linker 
with either HH residues (Table 2-1 line 26) or KQ residues (Table 2-1 line 32) 
also showed inhibition of CHO-IR cell extraction.  Because an SCI bearing only a 
single flanking R residue contiguous with Gly(A1) was effectively extracted 
(Table 2-1 lines 25, 27 and 29), the data suggest that a single arginyl side chain 
proximal to the A-chain may be an important feature for SCI interaction with 
insulin receptors (Fig. 2-3B), in addition to rendering the SCI effectively 
uncleavable (Fig. 2-2).  By contrast, it would appear that amino acid side chains 
in the mid-region of the linker are not critically important besides providing a 
flexible reverse turn, based on the efficient extraction of an SCI bearing only Gly 
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residues in the mid-region (Fig. 2-3B).  Moreover, constructs bearing multiple Gly 
residues in the mid-region also tended to exhibit higher secretory recovery of the 
recombinant SCI in the medium of transfected cells (Table 2-1).   
 
Cross-validation of SCI interactions with insulin receptors  
The ease of the extraction assay was particularly useful for ranking the relative 
efficiencies of receptor interaction of different SCIs.  Nevertheless, significant 
ligand depletion from the media during the course of this assay risks minimizing 
apparent differences in ligand affinity, which could be explained by cross-
reactivity with non-insulin receptors. Therefore, I cross-validated these results for 
selected constructs using a standard competitive binding assay with a fixed 
amount (12.5 fmoles) of 125iodoinsulin in the presence of a large excess of 
unlabeled ligand in varying concentrations (Fig. 2-4A).  CHO-IR cells were 
incubated at 4°C for six hours, after which the media was removed and cells 
were washed three times with PBS to remove all traces of unlabeled 125I-Insulin. 
The cell lysate was assessed for total counts using a gamma counter (Fig. 2-4A).  
IC50 for each construct was normalized as a fraction (%) of that observed for 
authentic insulin standard (Fig. 2-4B).  An SCI construct which directly links 
K(B29)-G(A1) (Table 2-1 line 1) that is known to lack significant activity on insulin 
receptors [29] could not compete for iodoinsulin binding (Fig. 2-4A).  Proinsulin 
(Table 2-1 line 36) similarly interacts only weakly with insulin receptors [93] (Fig. 
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2-4A).  By contrast, SCIs bearing the -GGGPGKR- linker [85] and our newly-
described -QRGGGGGQR- linker (Table 2-1 line 27) exhibited significant 
competition with iodoinsulin for insulin receptor binding (Fig. 2-4A), with the 
uncleavable SCI (-QRGGGGGQR- linker; Table 2-1 line 27) showing a binding 
affinity that is at least as strong or stronger than the SCI with the -GGGPGKR- 
linker (Table 2-1 line 15) that has been used in gene therapy of rodent diabetes 
[84].   
 
SCI activation of insulin receptors  
I next examined insulin receptor activation by SCIs in embryonic fibroblasts from 
mice (MEFs) genetically devoid of IGF1 receptors but stably overexpressing 
human insulin receptors [28], thereby eliminating any confusion about the source 
of SCI signaling.  Twelve minutes after addition of either chemically purified 
human insulin, or recombinant proinsulin or SCIs at 5 ng/mL, the MEFs were 
lysed in the presence of an anti-phosphatase cocktail and were analyzed by 
Western blotting with anti-phosphotyrosine (Fig. 2-5A, upper panel) or anti-
phospho-AKT (Fig. 2-5A, lower panel).  [Note again that the construct bearing an 
-RRGKR- linker (lane 5, and Table 2-1 line 12) is not a single-chain insulin].  The 
SCI with K(B29) tethered directly to G(A1) [Table 2-1 line 1] is known to exhibit 
nearly zero bioactivity [29] and yielded background autophosphorylation of insulin 
receptors (Fig. 2-5A, lane 4) comparable to that seen for proinsulin (lane 3), with 
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only slightly greater AKT phosphorylation than that observed in MEFs exposed to 
conditioned medium alone (lane 9).  By contrast, three other SCIs with linkers 
bearing an Arg residue before Gly(A1) each clearly stimulated 
autophosphorylation of insulin receptors, and each triggered downstream 
signaling to AKT (lanes 6-8), similar to that observed for authentic insulin (lane 
2).   
In additional experiments using an assay in which tracer 125iodoinsulin was pre-
bound to MEFs at 4°C prior to the addition of unlabeled ligand, I found that the 
kinetics of displacement of the tracer 125iodoinsulin into the medium upon 
addition of unlabeled SCI  bearing a -QRGGGGGQR- linker (Table 2-1 line 27) 
was at least as fast as that observed upon addition of unlabeled insulin, 
indicating that such an SCI is an effective mimic in ligand-induced dissociation of 
pre-bound insulin (not shown).  Moreover, upon addition of the same SCI to cells 
that had been serum-starved, the kinetics of insulin receptor autophosphorylation 
and downstream signaling to AKT also appeared comparably fast to that of 
insulin, with maximum signaling seen already by 6 minutes after ligand addition 
(Fig. 2-5C).   
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SCI-stimulated glucose uptake by adipocytes and suppression of 
gluconeogenic enyzme synthesis in hepatocytes   
To test whether SCI-mediated signaling resulted in standard metabolic effects of 
insulin, I first pre-incubated 3T3L1 adipocytes with various SCIs and then tested 
for 3H-2-deoxyglucose uptake over a 5 min test period (see Methods).  A 
negative control employed cells exposed to medium in which no recombinant SCI 
had been added (with uptake of ~120 pmoles deoxyglucose per minute per well 
of confluent 3T3L1 adipocytes).  An SCI directly linking K(B29)-G(A1) (Table 2-1 
line 1) in a largely inactive conformation [29], and proinsulin (Table 2-1 line 26) 
which has very low receptor activation [123] each exhibited minimal stimulation of 
2-deoxyglucose uptake (Fig. 2-6).  Authentic insulin (positive control, last bar) 
exhibited a > 4-fold increase in 3H-deoxyglucose uptake (slightly greater than that 
observed for the construct bearing an -RRGKR- linker which is cleaved to a two-
chain protein).  Two SCIs bearing a nonapeptide linker (-RRGGGGGQR- and the 
uncleavable -QRGGGGGQR-, Table 2-1 lines 29 and 27, respectively) exhibited 
comparably strong stimulation of deoxyglucose uptake (Fig. 2-6), exceeding that 
observed for the SCI (-GGGPGKR-, Table 2-1 line 15) that had been reported to 
be effective in lowering blood glucose in diabetic rodent models [85].   
Next, serum-starved primary rat hepatocytes were incubated for one day in 
media containing various recombinant SCIs and then were analyzed by 
quantitative PCR for mRNA encoding PEPCK, a key enzyme in gluconeogenesis 
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(Fig. 2-7A).  [Once again, addition of authentic insulin served as a positive control 
while the construct bearing an -RRGKR- linker is processed to a two-chain 
insulin molecule.]  Proinsulin was ineffective in suppressing mRNA levels for this 
gluconeogenic enzyme, but SCIs bearing linkers of -GGGPGKR-,                                
-RRGGGGGKR-, and -QRGGGGGQR- (Table 2-1 lines 15, 29, and 27) were 
similarly effective, with the uncleavable linker being perhaps being the best of 
this latter group.  Further, a replication-deficient recombinant adenovirus was 
engineered to encode this latter SCI, driven by an artificial promoter derived from 
a small region of the glucose-regulated L-type pyruvate kinase gene (nucleotides 
-201 to +12).  Beginning at 24 h after infection, primary rat hepatocytes were 
compared to those infected only with a Green Fluorescent Protein (GFP)-
expressing control adenovirus.  After an additional 24 h exposure to high 
glucose, glucose-induced expression of the SCI caused an ≥ 85% reduction in 
hepatocyte PEPCK mRNA compared to control values (Fig. 2-7B).  Together, the 
data in Figs. 2-5, 2-6, and 2-7 support that SCI bioactivity is coupled not only to 
kinase signaling but also to metabolic regulation in insulin-responsive target cells.   
 
Limited SCI activation of cell surface IGF1 receptors  
As IGF1 is a single-chain insulin-like molecule, the potential for cross-activation 
of IGF1 receptors by SCIs must be considered.  To assess cross-activation, I 
employed NIH-3T3 cells overexpressing IGF1 receptors [69] and examined IGF1 
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receptor autophosphorylation.  Twelve min after addition of either 10 ng/mL 
authentic IGF1, authentic insulin, or recombinant proinsulin or SCIs, the cells 
were lysed in the presence of an anti-phosphatase cocktail and were then 
analyzed by Western blotting with anti-phosphotyrosine.  Direct blotting of IGF1 
receptors in these lysates (lower panel, Fig. 2-5B) confirmed that gel loading was 
properly normalized.  A low-level phospho-IGF1R band was seen even in cells 
incubated with no ligand (upper panel of Fig. 2-5B, lane 1) or conditioned media 
from untransfected 293T cells (lane 3).  A strong phospho-IGF1R signal was 
elicited by authentic IGF ligand (lane 2), while proinsulin and each of the SCIs 
(lanes 5-8) exhibited low-level cross-activation of IGF1 receptors in a range 
similar to that observed for authentic insulin (Fig. 2- 5B, lane 4).   
 
2.4 Discussion 
 
In this report, I have been interested to further examine features of SCIs that 
might affect their potential for future use as insulin receptor agonists.  Without 
altering insulin B-chain or A-chain sequences, I designed several new SCIs 
(Table 2-1) built around a template design (line 19).  Functioning strictly as a 
single-chain protein, an SCI bearing a -QRGGGGGQR- linker sequence is one 
that I have been enthusiastic about as a polypeptide that folds with native 
disulfide bonds (as judged by nonreducing tris-tricine-urea-SDS-PAGE mobility, 
Fig. 2-2); is cleavage-resistant even in an endoprotease-enriched 
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microenvironment (Fig.2- 2); is efficiently extracted by cells overexpressing 
insulin receptors (Fig. 2-3); shows competitive binding with 125iodoinsulin that is 
at least as efficient as a construct previously used successfully for gene therapy 
in rodents (Fig. 2-4); stimulates insulin receptor autophosphorylation and 
downstream signaling to AKT (Fig. 2-5A); drives glucose uptake in adipocytes 
(Fig. 2- 6); and suppresses gluconeogenic enzyme synthesis in hepatocytes (Fig. 
2-7).  The only other cleavage-resistant constructs in this study involved direct 
linkage of insulin B- and A-chains, resulting in disulfide mispairing in the 
endoplasmic reticulum (Fig. 2) [100]; weak insulin receptor binding (Figs.  2-3A, 
2-4A); and little favorable downstream metabolic signaling (Figs. 2-5A, 2-6) [29].   
From this study, it appears that the best SCI ligands have an arginyl residue 
immediately preceding Gly(A1).  Replacement of basic residues at the carboxyl-
terminus of the linker sequence inhibits insulin receptor interaction (Table 2-1 
lines 21, 26, 32) even though the arginyl residue is not required as a cleavage 
site (Fig. 2-2).  One hypothesis would be that a basic residue can mimic a free 
amino group that would ordinarily be provided by the free amino group of Gly(A1) 
[91, 94] which is an important residue for receptor contact [124].  In future, this 
should be tested by engineering a lysyl residue in this position of the linker 
sequence.   
Excessive length of the linker (Table 2-1 lines 34 and 35) is obviously detrimental 
to insulin receptor interaction (Fig. 2-3A).  These findings appear to account for 
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the low bioactivity of proinsulin itself [59], which was in fact demonstrated herein 
(Figs. 2-3A, 2-4A, 2-5A, 2-6, and 2-7).  Very short linker sequences also 
appeared unfavorable in their ability to bind insulin receptors (Table 1, Fig. 2-3A).  
These data are consistent with the idea that a tethered C-terminal portion of the 
insulin B-chain limits good ligand contact with the receptor [114] while greater 
mobility in this region may unencumber the N-terminal portion of the insulin A-
chain [115].  The presence of a tight turn with a short linker is likely to seriously 
restrict such movement, while results with a pentapeptide -RRGKR- linker (Fig. 
2-5A, 2-6, and 2-7A) are not representative of SCIs with short linkers because 
this miniproinsulin is quantitatively converted to a 2-chain product as a 
consequence of its furin-like endoproeolytic cleavage site [168].  Work has not 
been done to determine to determine if cleavage of this construct occurs on both 
sides of the linker sequence or only at the A-chain junction. 
While SCIs produce many of the same favorable metabolic effects of authentic 
insulin (Figs. 2-6, 2-7), there are certainly still issues that must be addressed in 
the further development of SCIs as potential anti-diabetic therapies.  No work has 
yet been performed on the immune response to SCIs bearing foreign linker 
peptide sequences.  I also think it plausible that SCI native structure and 
immunogenicity might be exploited in vaccine development, since the insulin B-
chain 9-23 peptide [15, 23, 36] is thought to contain diabetes-associated epitopes 
of significance for disease in humans [4] as well as nonobese diabetic (NOD) 
mice [86, 117, 118, 126, 172].   
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In conclusion, the results described herein help to establish guidelines for the 
features of SCI linker sequences that are needed to confer native structure and 
bioactivity, and provide encouragement for their further development.   
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2.5 Methods 
 
Directed mutagenesis to generate distinct SCI constructs   
67 cDNAs encoding SCIs bearing distinct linker sequences (35 reported in this 
study) were generated using a 4-primer method using an SCI with direct B-chain-
to-A-chain linkage [100] as a template.  Briefly, two distinct initial rounds of PCR 
were employed using primer set 1+2 and primer set 3+4 in which primers 2 and 3 
include overlapping, complementary 20-mer oligonucleotide sequences that also 
contain unique sequence encoding the introduced mutagenized residues, while 
primer 1 (5’-ggtaccatggccctgtggatgcgcctcctgcc-3') and primer 4 (5’-
cctaagctagttgcagtagttctccagctggta-3') amplify the proinsulin signal peptide and 
the end of the insulin A-chain, respectively.  Finally, the purified products of the 
first two PCR reactions were mixed together as template, and a third round PCR 
was employed in which amplification used terminal, opposite stranded primer set 
1+4.  The resultant PCR product was ligated into the mammalian expression 
vector pTARGET (Promega) and confirmed by DNA sequencing.   
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Production of recombinant SCI protein   
In brief, 293T cells supplemented with Dulbecco's Modified Eagle Medium 
(DMEM, Gibco 11995) plus 10% FBS were transfected with plasmids encoding 
various SCIs using Lipofectamine 2000 (Invitrogen).  After 24 h, transfection 
medium was removed and cells were washed twice with PBS.  Cell culture media 
was then replaced with DMEM containing 1% fish-skin gelatin (rather than 
albumin or other serum constituents that may contain or bind insulin); preliminary 
studies established that cells transfected with empty vector remained healthy 
while yielding no background insulin immunoreactivity the media.  After a further 
48 h in culture, media were recovered and a radioimmunoassay designed to 
detect rat insulin-plus-proinsulin (ie, cross-reacting with all insulin-containing 
polypeptides, Linco Diagnostics) was employed to measure recombinant SCI 
concentration in each sample.  The use of SCIs in subsequent studies was then 
normalized to immuno-assayable levels.   
 
Steady-state, metabolic labeling to compare SCI expression levels   
The determination of relative concentration of selected SCI constructs was cross-
checked by steady-state radiolabeling, based on the fact that all constructs had 
an identical number of Cys residues per molecule.  In brief, 10 µcCi 35S-Cysteine 
(without methionine) was added to complete culture medium (to achieve a fixed 
specific radioactivity) and the cells were labeled continuously in this medium for 
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24 h to approach steady state.  The samples were then split in two aliquots.  To 
one aliquot, RIA was used to measure the relative immuno-assayable SCI levels 
in comparison to an insulin standard.  Note: we confirmed that 35S-cysteine does 
not in any way interfere with the gamma counting that is used to detect 125I-
insulin from the RIA.  To the second aliquot, SCIs were immunoprecipitated with 
a vast excess of polyclonal guinea pig anti-(porcine)-insulin (Linco; pilot re-
precipitation experiments confirmed that a saturating quantity of this 
immunoprecipitating antibody was used).  Zysorbin (Zymed) was used to recover 
the immunoprecipitates, which were washed several times before addition of 
SDS-gel sample buffer including 100 mM dithiothreitol.  Denaturation was 
completed by boiling each sample for 5 min.  Fully reduced SCIs in these 
samples were analyzed by tris-tricine-urea-SDS-PAGE, fluorography, and the 
amounts quantified by scanning densitometry.   
 
SCI interaction with insulin receptors 
For an estimate of receptor interaction that did not require radioiodination of the 
ligand(s), recombinant SCIs synthesized in 293T cells were diluted to a stock 
concentration of 50 ng/ml and then further diluted 10-fold to a final concentration 
of 5 ng/mL in conditioned media from untransfected 293T cells that had been 
incubated (in batch) in DMEM plus 1% fish skin gelatin.   Standards were also 
diluted in this medium.  CHO-IR cells that overexpress human insulin receptors 
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were grown to confluency in Ham's F12 medium (GIBCO #11765) plus 10% FBS 
in 12-well plates.  CHO-IR cells were then serum starved overnight in F12 
containing 11 mM glucose, and then 500 µL of SCI or standard was applied to 
the cells for 6 h at 4°C.  After incubation, media was removed and the remaining 
soluble SCI was re-measured by RIA; the calculated difference value reflected 
the amount extracted by binding to CHO-IR cells.   
In competitive binding experiments, CHO-IR cells were incubated for 6 h at 4°C 
with varying concentrations of unlabeled SCI or human insulin in the presence of 
a fixed amount (12.5 femtomoles) of 125I-labeled human insulin (Amersham 
Biosciences cat. #IM166).  After incubation, the media were removed and cells 
washed three times with PBS to remove unbound 125I-insulin. The cells were then 
lysed and counted in a gamma counter, in triplicate.  At each concentration of 
cold competitor, the data were plotted as a percent of total counts bound when 
unlabeled ligand concentration was zero.  IC50 values were determined using 
GraphPad Prism software by curve-fitting with a one-site competition model.   
 
Phosphorylation of insulin receptors, IGF1 receptors, and AKT   
Mouse embryonic fibroblasts lacking IGF1 receptors and overexpressing human 
insulin receptor B-isoform ("R–IR-B cells" [28], kindly provided by Dr. C. T. 
Roberts at Oregon Health and Science University, Portland OR) or NIH-3T3 cells 
overexpressing IGF1 receptors ([69], kindly provided by Dr. D. LeRoith, Mount 
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Sinai School of Medicine, New York NY) were serum-starved overnight.  The R–
IR-B cells were washed and then incubated with 500 µL of media containing 5 
ng/mL of each SCI [in conditioned media from untransfected 293T cells that had 
been incubated (in batch) in DMEM plus 1% fish skin gelatin; standards were 
also diluted in this medium] in a cell culture incubator for 12 min at 37°C.  The 
NIH-3T3 cells overexpressing IGF1 receptors were washed and similarly 
incubated with IGF1 or SCIs.  Media was then removed and the cells washed 
twice with ice-cold PBS.  Cells were lysed in 150 mM NaCl, 1% NP-40, 0.1% 
SDS, 2 mM EDTA, 10 mM Tris-HCl pH 7.4 plus 1% protease inhibitor cocktail 
(Roche #11836153001) and 1% phosphatase inhibitor cocktail (Sigma #P2850 
plus #P5726).  The samples (40 µg cell protein) were then analyzed by SDS 
10%-PAGE and Western blotting with mouse mAb anti-phosphotyrosine (clone 
4G10, Millipore #05-321) followed by a peroxidase-conjugated goat anti-mouse 
IgG (Bio-Rad #170-6516).  As a control to confirm band identity, samples were 
also Western blotted with rabbit polyclonal antibodies against insulin receptor 
(Santa Cruz #C-19) or IGF1 receptor Santa Cruz #C-20), each followed by a 
peroxidase-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch #111-
035-003).  Phospho-Ser473 of AKT (referred to as phospho-AKT) was blotted 
with a mouse mAb (Cell Signaling #9271).  As a control to confirm band identify, 
samples were also Western blotted with rabbit polyclonal anti-AKT (Millipore 
#9272) and appropriate peroxidase-conjugated secondary antibody.  All primary 
antibodies were used at a dilution of 1:1000, anti-mouse IgG secondary 
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antibodies were used at 1:3,000 and anti-rabbit IgG secondary antibodies were 
used at 1:10,000.   
 
SCI-stimulated glucose uptake   
Mouse 3T3L1 preadipocytes were maintained in DMEM plus 10% calf serum, 
and were induced to differentiate into adipocytes 3 d after achieving confluency in 
12-well plates by addition of 100 µg/ml insulin, 1 µM dexamethasone, and 0.5 
mM isobutyl-1-methylzanthine for 3 d and followed further by 100 µg/ml insulin for 
2 d as previously described [16].  SCIs synthesized as recombinant proteins 
expressed in 293T cells were diluted to a stock concentration of 50 ng/ml in 
DMEM plus 1% fish-skin gelatin and then further diluted 10-fold in Hepes-
buffered Krebs-Ringers-Bicarbonate (KRBH: 10 mM NaHCO3, 120 mM NaCl, 4 
mM KH2PO4, 1 mM MgSO4, CaCl2, 30 mM Hepes pH 7.4) to a final concentration 
of 5 ng/mL plus a final (nonradioactive) glucose concentration of 4 mg/100 mL.  
The differentiated 3T3L1 adipocytes were then preincubated for 3 h in DMEM 
containing 5.5 mM glucose plus 0.2% FBS.  The cells were then washed once, 
and 500 µL of KRBH containing each SCI was added to cells in a cell culture 
incubator at 37°C.  After 30 min, 1 µCi 3H-deoxy-D-glucose (~45 nmoles, MPBio 
cat. #27088S) was added to each well for a further incubation of 5 min.  The 
reaction was stopped by addition of 50 µL of 200 mM nonradiactive glucose per 
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well, rapidly washing three times with ice-cold PBS, and then lysis in 0.1% SDS 
(500 µL) for scintillation counting.   
 
The potential for SCI endoproteolysis as measured in AtT20 cells   
The potential for cleavage of SCIs was assessed after transient transfection in 
AtT20/PC2 cells (a kind gift of Dr. R. Mains. U. of Connecticut, Farmington CT).  
The cells were pulse-labeled for 30 min with 35S-Cys/Met mixture and chased for 
3 h under unstimulated conditions.  At that time media was replaced with fresh 
chase media ± 5 mM BaCl2 and the cells chased for an additional 30 min.  The 
stimulated or unstimulated secretion was collected and immunoprecipitated with 
polyclonal guinea pig anti-(porcine)-insulin.  SCI immunoprecipitates were 
analyzed by tris-tricine-urea-SDS-PAGE and fluorography.   
 
Preparation of primary rat hepatocytes   
Hepatocytes were obtained from livers of male Sprague-Dawley rats (Harlan) by 
collagenase perfusion as previously described [27].  Rat primary hepatocytes 
were plated in RPMI 1640 media containing 11 mM glucose, 10 % FBS, 100 nM 
dexamethasone, and 100 nM insulin.  At 4 h after plating, nonadherent cells were 
aspirated and adherent cells were further incubated for adenoviral infection.   
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Adenoviral infection of primary rat hepatocytes   
The pGL3-basic vector (Promega) was used to construct different promoter-
driven versions of the SCI #3 construct.  PCR of rat genomic DNA was used to 
generate promoter sequences from the rat liver pyruvate kinase (L-PK) from 
nucleotide -201 to  +12 (forward primer with SacI site: 5’-
TCCGAGCTCTGCAGACAGGCCAAAGG-3’; reverse primer with BglII site: 5’-
CATAGATCT ACGTTGCTTACCTGCTG-3’) which was inserted between the 
SacI and BglII sites of pGL3-basic.  The SCI with a -QRGGGGGQR- linker 
sequence was engineered to be inserted between NcoI and XbaI sites within the 
above shuttle vectors.  After DNA sequence confirmation, the different glucose-
inducible promoter-driven versions of this SCI were inserted between the KpnI 
and SalI sites of the promoterless pAdTrack (www.coloncancer.org).  The 
pAdTrack-promoter-SCI constructs were digested with PmeI and cotransformed 
by electroporation in BJ5183 cells with the pAdEasy-1 adenoviral gene 
backbone, with positive clones selected and diagnostically confirmed by plasmid 
miniprep and PacI digestion (as well as direct sequence confirmation).  After 
maxi-prep purification, PacI linearized adenoviral DNA was used for transfection 
to produce virions in 293 cells used as the viral packaging cell line.  
Adenoviruses expressing green fluorescent protein (GFP) as well as the glucose-
inducible regulatory element driven SCI were purified on cesium chloride 
gradients.  After adenovirus plaque assay, primary rat hepatocytes were infected 
at a multiplicity of infection of 50.  After viral addition, the medium was changed 
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to RPMI 1640 with 5.5 mM glucose, and the cells incubated overnight before 
another medium change to RPMI 1640 containing 25 mM glucose for 24 h.  At 
this time, RNA was isolated from the hepatocytes using the RNeasy kit (Qiagen) 
as per the manufacturer's instructions.  
 
Real-time PCR   
Isolated RNA was initially treated with DNase I at 37°C for 1 h before quenching 
with DNase inactivation reagent (Ambion).  1 µg of DNA-free RNA from each 
sample was used for first-strand cDNA synthesis in the presence of 10 mM dNTP 
mix and 1 µL of random hexamers (50 ng/µl).  Each sample was incubated at 
70°C for 10 min and then placed on ice.  Next, 2 µL of 10x reverse transcription 
buffer, 4.5 µL of 25 mM MgCl2, 2 µL of 0.1 M dithiothreitol, and 1 µL of 
RNaseOUT recombinant ribonuclease inhibitor was added to each tube.  After 
incubation at 25°C for 2 min, each tube was loaded with 1 µL of SuperScript III 
reverse transcriptase.  The tubes were incubated at 25°C for 10 min, 42 °C for 1 
h, and 85 °C for 15 min.  RNase H was added to each to each tube and 
incubated at 37°C for 20 min.  The parameters for real-time PCR were as follows: 
95°C for 11 min followed by 40 cycles of 95°C for 30 s and 60°C for 1 min and, 
for the melt curve, 100 cycles of 10 s from 60 to 100°C in 0.4°C increments.  The 
final concentration of primers in each PCR well was 0.1 µM.  Oligonucleotide 
standards were serially diluted from 10–5 µM to 10–9 µM to be used as template 
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for a standard curve.  The rat PEPCK forward primer was 5'-
TGAGGAAGTTTGTGGAAGGCA-3' and reverse primer was 5'-
GCCGTCGCAGATGTGAATATACT-3'.  An 18S rRNA primer set was also 
employed (forward primer 5'-CGGCTACCACATCCAAGGAA-3' and reverse 
primer 5'-TTTTCGTCACTACCTCCCCG-3' [102].  1 µL of a 1:50 dilution of each 
cDNA was used as a template to assess either PEPCK mRNA or 18S rRNA 
(which was used to normalize the PEPCK mRNA measurements).  
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2.6 Figures 
 
Figure 2-1. Comparison of SCI levels measured by RIA to that measured by 
steady state metabolic labeling.   
293T cells were transiently transfected with cDNAs encoding SCIs containing the 
linker sequences shown at the top of the Figure.  The 'Direct Linkage' construct 
(lane 1; also Table 1 line 2) fuses the insulin B-chain Thr(B30) to the A-chain 
Gly(A1) with no intervening sequence.  The other constructs expressed 
contained the following linkers: -MGGM- (lane 2, also Table 1 line 11); -
GGGPGKR- (lane 3, also Table 1 line 15); -QRGGGGGQR- (lane 4, also Table 1 
line 27); and -RRGGGGGKR- (lane 5, also Table 1 line 20).  Transfected 293T 
cells were labeled continuously for 24 h with 35S-Cysteine at a fixed specific 
radioactivity to approach steady state.  Media were analyzed both by RIA (values 
for each sample shown at bottom) and by immunoprecipitation with a saturating 
amount of antibody (see Methods) followed by reducing tris-tricine-urea-SDS-
PAGE and fluorography.  A representative experiment (of three) is shown.  The 
relative gel band densities for each construct were within 10% of the RIA 
readings when the smaller fragments shown in lanes 1 and 2 (not seen in all 
experiments) were included in the densitometry.  Note that the Direct Linkage 
construct has a molecular mass of 5.8 kD, identical to that of human insulin.   
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Figure 2-2. Cleavage of SCIs in the secretory granule environment of 
AtT20/PC2 cells.   
Cells were either untransfected ("Control") or transiently transfected with the 
constructs bearing the linkers shown.  For proinsulin (molecular mass = 9.4 kD) 
the linker is C-peptide.  The other linkers are -QRGGGGGQR- (Table 1 line 27 
-GGGPGKR- (Table 1 line 15), Direct Linkage (Table 1 line 2), -RRGGGGGKR- 
(Table 1 line 20), and  -RRYLGGGGGGGDVKR- (Table 1 line 34).   The cells 
were pulse-labeled for 30 min with 35S-amino acids.  After the first 3 h of chase, 
fresh chase media was added for 30 min in the absence of secretagogues ("Stim 
–"), and then for an additional 30 min in the presence of 1 mM BaCl2 ("Stim +").  
Media were immunoprecipitated with anti-insulin, which was analyzed by tris-
tricine-urea-SDS-PAGE under nonreducing conditions.  Mature insulin has a 
molecular mass 5.8 kD. 
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Figure 2-3. Extraction of SCIs, or insulin standard, from media bathing 
CHO-IR cells (overexpressing human insulin receptors).    
First, the recombinant proteins were produced in transfected 293T cells.  Then, 
confluent CHO-IR cells that had been serum starved overnight in 12-well plates 
underwent a medium change to contain 500 µL conditioned media containing 
recombinant SCI that had been diluted to 5 ng/mL in fresh medium.  The 
samples were cooled to 4°C and incubated for 6 h at 4°C.  SCI extraction from 
the media was measured using an RIA for (proinsulin+insulin) that cross-reacts 
with unprocessed and processed products of multiple species.  The 'Direct 
Linkage' construct, in which the insulin B-chain Thr(B30) is directly linked to the 
A-chain Gly(A1), served as a negative control (white bar, panel A, left).  Purified 
human insulin served as a positive control (white bar, panel B, right), and all 
extraction data were normalized to that observed for this standard (set at 100%; 
actual human insulin extraction in this assay was 85%).  The mean +/- standard 
deviations of three independent experiments are shown.  (A) SCI extraction as a 
function of unusually short or extended linker length.  The 'C-peptide' linker 
represents native recombinant proinsulin.  (B) Mutation of dibasic sites at the 
amino and carboxyl-terminal ends of the linker sequence.   
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Figure 2-4. Competitive binding of recombinant SCIs (produced in 
transfected 293T cells) with 125iodoinsulin.   
Representative experiment (of three) of CHO-IR cells co-incubated with a fixed 
concentration of 125iodoinsulin and varying concentrations of authentic human 
insulin or SCIs bearing the following linkers: [C-peptide (proinsulin, Table 1 line 
36); -QRGGGGGQR-, Table 1 line 27); -GGGPGKR- (Table 1 line 15); or B29-A1 
(Table 1 line 1) for 6 h at 4°C.  (A) The media were removed and the cells 
washed once with ice cold PBS before counting the cell lysates in a gamma 
counter.  Standard deviations in these measurements are ~15% of mean values.  
(B) From curve-fitting of the data plotted in panel A, IC50 values for the SCI with 
a linker sequence -QRGGGGGQR- is compared against that of the published 
SCI from Table 1 line 15 [85], normalized as a fraction (%) of that observed for 
authentic human insulin standard (white bar).   
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Figure 2-5. Kinase activation of insulin receptors and IGF1 receptors by 
recombinant SCIs (produced in transfected 293T cells).   
 (A) Confluent serum starved mouse embryonic fibroblasts (MEFs, from IGF1 
receptor null mice, overexpressing human insulin receptors) in 12-well plates 
were incubated in 500 µl of media containing 5 ng/mL of each SCI or insulin 
standard for 12 min at 37°C.  Cells were washed and lysed in the presence of 
phosphatase inhibitors as described in Methods.  The samples were resolved by 
SDS-PAGE, electrotransferred to nitrocellulose, and Western blotted with anti-
phosphotyrosine (upper panel) or anti-phosphoAKT (lower panel) as described in 
Methods.  The "Control" sample had no medium change from serum starved 
medium.  Lane 2 is a positive control incubated with chemically purified human 
insulin; lane 9 is a negative control incubated with conditioned medium from 
untransfected 293T cells.  Separate Western blotting of these samples were also 
performed with antibodies against insulin receptor (not shown) to confirm the 
identify of the bands shown in the upper panel and to serve as a loading control.  
(B) Confluent serum starved NIH3T3 cells overexpressing IGF1 receptors in 12-
well plates were incubated in 500 µl of media containing 10 ng/mL of each SCI or 
insulin standard for 12 min at 37°C, exactly as in  (A).  Cells were washed and 
lysed in the presence of phosphatase inhibitors as described in Methods and the 
samples analyzed by SDS-PAGE with Western blotting using with anti-
phosphotyrosine (upper panel) or anti-IGF1 receptor (lower panel, which serves 
as a loading control).  Note that the SCI  bearing a -QRGGGGGQR- linker is run 
in lane 8 in panel A and lane 6 in panel B (see double headed arrow in Figure).   
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Figure 2-6. 3H-deoxyglucose uptake in 3T3L1 adipocytes. 
Differentiated 3T3L1 adipocytes were serum starved in DMEM containing 5.5mM 
glucose, 0.02% FBS for 3 h.  Recombinant SCIs  (produced in transfected 293T 
cells) were diluted into KRBH buffer (containing 4 mg/100 mL nonradioactive 
glucose) to a final concentration of 5 ng/mL.  After a 30 min incubation at 37°C, 
3H-deoxyglucose uptake was performed for 5 min as described in Methods, 
followed by scintillation counting.  The linker sequences for each SCI construct 
are listed beneath each bar.  A negative control (white bar, left) includes 
conditioned medium bearing no SCI and a positive control (white bar, right) 
contains authentic human insulin; the linker called "Cpeptide" represents 
recombinant proinsulin.  
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Figure 2-7. A single-chain insulin bearing a -QRGGGGGQR- linker (Table 1 line 
27) suppresses gluconeogenesis in primary rat hepatocytes.   
Primary rat hepatocytes were prepared as described in Methods.  (A) Cells were 
first serum starved in RPMI-1640 medium containing 5.5 mM glucose, and then 
incubated in the same media containing 5 ng/mL of proinsulin (“Pro”), insulin, or 
the SCIs shown.  A negative control ("Neg. Con", white bar, left) had no SCI 
added, a positive control (white bar, right) included authentic human insulin.  
After 2 h of incubation, cells were lysed and PEPCK mRNA was measured by 
real-time PCR.  (B) Cells were infected by replication-deficient adenoviral vectors 
expressing either GFP alone ("Neg. Con", white bar) or the SCI bearing a -
QRGGGGGQR- linker, driven by nucleotides –201/+12 of rat liver pyruvate 
kinase ("L-PK").  At 24 h after infection, the cells were incubated in RPMI-1640 
media containing 25 mM glucose for a further 24 h before RNA was purified and 
analyzed for PEPCK mRNA abundance by real-time PCR.  The data shown in 
both panels are the mean ± S.E. from three independent preparations of 
hepatocytes.  
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  Linker Sequence Length Dibasic? Secretory Recovery Extraction Screen 
1 B29-A1 -1 N L NS 
2 Direct Linkage 0 N H NS 
3 M 1 N H NS 
4 GG 2 N M NS 
5 RR 2 Y M NS 
6 KR 2 Y M NS 
7 MM 2 N M NS 
8 GGG 3 N M NS 
9 GKR 3 Y M NS 
10 GGGG 4 N M NS 
11 MGGM 4 N M NS 
12 RRGKR 5 Y* L +++ 
13 MGGGGM 6 N M NS 
14 MGGGGGM 7 N M NS 
15 GGGPGKR 7 Y H +++ 
16 RRGPGKR 7 Y L +++ 
17 MGGGGGGM 8 N M ++ 
18 RRYPGDVKR 9 Y L +++ 
19 RRYLGDVKR 9 Y L +++ 
20 RRGGGGGKR 9 Y M +++ 
21 RRYLGDVGG 9 Y L + 
22 GGYLGDVKR 9 Y L +++ 
23 RQYLGDVKR 9 Y L +++ 
24 FFYLGVDKR 9 Y L NS 
25 RRYLGDVGR 9 Y L +++ 
26 RRYLGDVHH 9 Y L NS 
27 QRGGGGGQR 9 N M +++ 
28 QRGGGGGKR 9 Y L +++ 
29 RRGGGGGQR 9 Y L +++ 
30 MGGGGGGGM 9 N M NS 
31 GGGGGGGGG 9 N M NS 
32 RQYLGDVKQ 9 N L + 
33 RRYLGGGDVKR 11 Y L +++ 
34 RRYLGGGGGGGDVKR 15 Y L ++ 
35 RRYLGGGGGGGGGGGGDVKR 20 Y L + 
36 Full C-peptide 35 Y L + 
  
 
Table 1. SCI constructs prepared for this study.   
Except for the first construct shown, cDNAs encoding SCIs bear fixed B-chain/A-
chain sequences, ie, varying only by the sequences (shown in Table) that link B-
chain to A-chain.  The linkers vary in specific sequence and in length.  The 
presence or absence of dibasic sequences in any portion of the linker is indicated 
as a Yes (Y) or No (N), with one construct (line 12) yielding a predicted furin-type 
cleavage sequence (this construct on line 12, is indicated with asterisk because it 
is not a single-chain protein, being quantitatively cleaved in the secretory 
pathway of 293T cells).  Immunoassayed SCI recovery in the conditioned media 
bathing transfected 293T cells (a measure of both protein expression and 
secretability) was characterized as: Low (L, < 20 ng/mL recovered), Medium (M, 
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20 – 50 ng/mL recovered), or High (H, 50 – 100 ng/mL recovered).  A screening 
assay of the ability of various SCIs to be extracted from conditioned media by 
CHO-IR cells overexpressing insulin receptors, which correlates with receptor 
binding (see text), was characterized as:   NS (≤ 25 % extracted), + (25 – 50 % 
extracted), ++ (50 – 75 %), +++ (> 75 % extracted).  Constructs from this with 
data explicitly shown in the Figures are designated in italics.  Work presented in 
this manuscript highlights the SCI with a –QRGGGGGQR- linker (line 27 in bold) 
because of a balance of favorable properties.   
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CHAPTER 3  ENDOPLASMIC RETICULUM 
OXIDOREDUCTASES AND PROINSULIN FOLDING 
 
 
3.1 Abstract: 
 
Disulfide bond formation is critically dependent upon the local environment; 
intracellularly, multiple host-cell gene products provide the environmental and 
compartment-specific control in which these reactions take place.  Indeed, in the 
secretory pathway of cells, rather than being spontaneous, disulfide bond 
formation in biologically active peptides is primarily catalyzed, by PDI-like 
oxidoreductases.  In vitro studies provide a solid understanding of the spectrum 
of enzymatic capabilities of PDI and related family members.  However, these in 
vitro studies cannot replicate the complexity of the oxidoreductase working 
environment within the secretory pathway.  In the yeast ER — which may be 
more a more oxidizing environment than the ER of mammalian cells — there is 
strong evidence that PDI facilitates disulfide bond formation in exportable protein 
substrates, with evidence also supporting a role for PDI in disulfide isomerization  
and possibly reduction.  In mammalian cells, past literature has tended to group 
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PDI-like family members as if they were a single protein, but more recent 
evidence points to the idea that distinct PDI-like family members are 
subspecialized for somewhat different (albeit overlapping) in vivo functions.  This 
probably reflects differences in their relative redox setpoints, 
alterations/modifications of their catalytic CXXC sequences and neighboring 
residues, differences in their hydrophobic pockets for substrate binding and 
chaperone function, and differences in their ER resident partners that provide 
substrate specificity and function.  A case in point is for proinsulin folding in 
pancreatic beta cells: in vitro results support a role for PDI in proinsulin disulfide 
bond formation while thus far limited results in beta cells provide limited support 
for this view.  In this Chapter, I attempted to characterize the action of PDI on 
proinsulin in pancreatic beta cells.  I provide evidence that PDI directly interacts 
with proinsulin, and that PDI-knockdown actually increases proinsulin export as 
well as insulin production.  As opposed to widely held assumptions, my results 
are consistent with a model in which PDI exhibits unfoldase activity for proinsulin, 
increasing the retention of proinsulin within the ER of pancreatic β-cells, which 
decreases insulin production.  Interestingly, my results point to another ER 
oxidoreductase, ERp72, as a candidate oxidase (foldase) for proinsulin in the ER 
of pancreatic β-cells. 
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Significance:  Currently only one paper has been published attempting to 
ascertain the role of PDI in insulin production in the context of pancreatic beta 
cells[171].  The previous report employed an overexpression system for PDI to 
ascertain a role in pancreatic beta cells, and thus may have limitations because 
of an unphysiological expression level of PDI not observed in normal beta cells. 
The previous paper also did not look at a direct role of PDI in proinsulin folding, 
using secretion of insulin and intracellular content as a surrogate measure of 
folding. My research looks at the role of PDI using physiologically relevant 
knockdown studies. In addition to looking at the secretion of insulin, my research 
also looks directly at the folding of newly synthesized proinsulin. The maturation 
of proinsulin to insulin, employed as a barometer of ER Exit and as an indirect 
measurement of proinsulin folding, is also measured. During the course of the 
research work, data pointed to another PDI family member, ERp72, potentially 
involved in the oxidation and formation of proinsulin disulfide bonds. The role of 
ERp72, among the most abundant ER oxidoreductases expressed in pancreatic 
beta cells, also has not been studied in mammalian cell culture systems. This 
thesis work provides insight into the role ER oxidoreductases in proinsulin egress 
through the secretory pathway.  
 56 
 
 
3.2 Introduction 
 
Disulfide bonds are made in nearly one-third (7000) of the proteins in the 
eukaryotic proteome [48], many of which are destined for contact with the 
relatively non-reducing extracellular environment as secretory or cell surface 
proteins.  Disulfide bond formation involves a reaction between the sulfhydryl 
(SH) side chains of two cysteine residues: an S- anion from one sulfhydryl group 
acts as a nucleophile, attacking the side chain of a second cysteine to create a 
disulfide bond, and in the process releases two electrons (reducing equivalents) 
for transfer.  Proper disulfide bonds provide stability to a protein, decreasing 
further entropic choice, which facilitates folding progression towards the native 
state by limiting unfolded or improperly folded conformations.  An increase in 
stability of the native structure resulting from the formation of a particular disulfide 
bond is roughly proportional to the number of residues between the linked 
cysteines; i.e., the larger the number of residues in the ‘disulfide loop’, the 
greater the stability provided to the native structure [103, 121].   
The chemistry of protein disulfide bond formation is directly influenced by three 
key factors: 1) the spatial accessibility/physical proximity of the partner cysteine 
residues forming the disulfide bond; 2) the difference between the pKa of the 
involved thiol groups and the pH of the local environment (with lower pH limiting 
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reactivity and higher pH favoring increased reactivity); and 3) the redox 
environment (with lesser reactivity under more reducing conditions and greater 
reactivity under more oxidizing conditions) [9, 103, 138, 163].  As the latter two 
factors are environmentally controlled, specific cellular compartments have 
evolved within cells to facilitate disulfide bond formation.  In bacteria, disulfide 
bonds in bioactive peptides and polypeptides of the secretory pathway are 
formed in the periplasm; in eukaryotes, such (poly)peptides tend to acquire their 
disulfide bonds in the endoplasmic reticulum (ER) . The ER is a vastly more 
common site than the cytosol for disulfide formation (which is very rarely the site 
of disulfide bond formation) because the ER intralumenal environment is more 
oxidizing than that of the cytosol [5].  The redox environment is at least in part 
reflected by the ratio of oxidized glutathione (GSSG) to reduced glutathione 
(GSH), which in the case of the ER (and periplasm), is shifted in favor of GSSG 
[5].  
 
3.2.1 The Concept of Secretory Pathway Catalysis of Disulfide Bond 
Formation 
 
Although disulfide bonds can form spontaneously (albeit very slowly) via 
molecular oxygen or directly via oxidized glutathione as an electron acceptor, the 
main mechanism of disulfide bond formation in the secretory pathway involves 
enzymatic catalysis, via oxidoreductase proteins bearing a catalytically active 
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thioredoxin domain motif: CXXC (where ‘X’ residues tend to be hydrophobic 
amino acids) that is responsible for disulfide bond transfer from oxidoreductase 
to substrate [48].   In secretory proteins that contain more than one disulfide bond 
in their final structure, the formation of these bonds is typically not a linear 
process, insofar as their order of formation may vary en route to the native state.  
In general, newly-synthesized secretory proteins have preferred folding 
intermediates (such as has been become well known from in vitro folding studies 
of ribonuclease and bovine pancreatic trypsin inhibitor [26, 103, 138]).  
Oxidoreductases may help to promote a particular folding pathway both by 
selective disulfide catalysis and by acting as molecular chaperones that limit off-
pathway folding choices.  Once a transient intramolecular disulfide bond has 
formed within the CXXC motif of the oxidoreductase, the catalytic event proceeds 
via a transient mixed disulfide bond between the amino-terminal cysteine of the 
CXXC and the substrate protein, which is then resolved by completion of an 
intramolecular disulfide bond formed within the substrate protein (Fig. 3-1) in a 
process facilitated by both the carboxyl-terminal cysteine of the CXXC motif and 
neighboring residues that influence the CXXC redox potential.  Catalyzed 
disulfide bond formation occurs very rapidly, with dynamic sampling and release 
of substrate proteins by oxidoreductase enzymes [6, 47].  The reaction catalyzing 
disulfide transfer to the substrate protein does not result in a net loss or gain of 
disulfide bonds, as a reduced CXXC motif is regenerated in the disulfide transfer 
process; i.e., the transfer reaction involves oxidation of the substrate protein 
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concomitant with reduction of the thioredoxin motif in the oxidoreductase.  Thus, 
within the ER, there is a net flow of electrons from substrate proteins to 
oxidoreductases that catalyze disulfide bond formation.  In the ER of 
eukaroyotes, Protein Disulfide Isomerase (PDI) is the most prominent and most 
evolutionarily conserved of these oxidoreductases — but there are at least 21 
PDI-like family members in mammalian cells [48, 128] — several of which shall 
be touched upon in this Introduction (Table 3-1).   
The secretory pathway operates as a protein manufacturing and export factory.  
Once properly folded, the most recent cohort of oxidized secretory proteins is 
exported, only to be immediately followed by a new cohort of incoming (newly-
synthesized) secretory proteins — and these new polypeptides begin their 'life' 
with a full complement of reduced cysteine thiols.  In order to bring about another 
round of substrate protein oxidation, the catalytic oxidoreductases must again 
form a transient intramolecular disulfide bond within their CXXC motif(s); thus, 
they must become re-oxidized.  In bacteria, secretory protein oxidation by the 
Disulfide Bond Formation (DSB) family of proteins begins with DsbA catalyzing 
initial disulfide bond formation in substrates, with DsbA being re-oxidized by 
electron transfer to the periplasmic membrane-bound DsbB (from which 
electrons are subsequently ‘unloaded’ to ubiquinone that is finally reoxidized by 
the respiratory chain involving molecular oxygen as the terminal electron 
acceptor [12, 65, 103]).  In the secretory pathway of eukaryotes, the various ER 
oxidoreductases also must become re-oxidized, and the identity of the reoxidant 
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is still somewhat unclear, however, this is an extremely active area of ongoing 
investigation.  PDI (encoded by the P4HB gene) can be specifically re-oxidized 
by Endoplasmic Reticulum Oxidoreductin-1 (ERO1), an ER membrane-
associated protein that serves as the functional analog of bacterial DsbB [6, 7, 
39, 40].  In yeast, ERO1 was first identified because its genetic deletion resulted 
in a phenotype in which exportable proteins lacked disulfide bonds [39].  Indeed, 
ERO1 was found to form a transient mixed disulfide with PDI and yet ERO1 
appeared unable to interact directly with exportable protein substrates [40].  
Moreover, overexpression of ERO1 itself cannot rescue perturbation of disulfide 
bond formation resulting from PDI knockout, strongly suggesting that, at least in 
S. cerevisiae, oxidized PDI is required for ongoing disulfide bond formation in 
secretory proteins and ERO1 is required for the catalytic re-oxidation of PDI [40].  
From these and additional studies performed in higher eukaryotic cells and 
animals [5][5-7, 142, 175], ERO1 proteins are now considered to be one of the 
major catalysts of disulfide bond formation in the ER lumen [142] — although still 
under active investigation are possible important roles for other oxidizers of 
lumenal ER oxidoreductases and substrate proteins — including oxidized 
glutathione (discussed above) plus additional enzymes  including but not limited 
to Peroxiredoxin 4 (PRDX4) , Vitamin K-dependent OxidoReductase (VKOR), 
and Quiescin–Sulfhydryl OXidase (QSOX), (discussed below) [5].   
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3.2.2 Transfer of Reducing Equivalents from the ER Lumen to the 
Cytosol 
 
ERO1, containing a variant of the thioredoxin motif known as a cysteine triad, 
provides a mechanism for delivery of reducing equivalents back to the cytosol, 
leading ultimately to molecular O2 [142].  In the case of the mammalian gene 
product, whereas the last two cysteines of the amino-terminal cysteine triad 
(residues C94 and C99) of ERO1 catalytically transfer a disulfide bond to the 
active site of PDI, the last two cysteines of the carboxyl-terminal triad (residues 
C394 and C397) of ERO1 are used to transfer reducing equivalents to FAD+ [13].  
Reducing equivalents are internally shuttled within ERO1 from C94/C99 to 
C394/397, in order to ready C94/C99 for another round of disulfide bond 
formation.  The reduction of FAD+ to FADH2 (which, in the cytosol, can transfer 
these reducing equivalents to molecular oxygen as the terminal electron 
acceptor) is accompanied by formation of hydrogen peroxide (H2O2) in the ER, 
as a byproduct [142].  The stoichiometry is such that for every ERO1-catalyzed 
disulfide bond, one molecule of hydrogen peroxide is generated.   
 
As H2O2 is one form of Reactive Oxygen Species (ROS), the catalytic activity of 
ERO1 has been considered a contributor to cellular oxidative stress that is seen 
an undesirable outcome [142], although this has been debated [5].  New studies 
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indicate that Peroxiredoxin 4 (PRDX4) links the reduction of cytoplasmic 
hydrogen peroxide to additional disulfide bond formation in PDI-like 
oxidoreductases of the ER lumen [17, 176].  In the process of reducing H2O2, 
PRDX4 becomes chemically oxidized at the carboxyl-terminal cysteine of its 
CXXC motif, followed by formation of a mixed disulfide bond that is transferred to 
PDI or other PDI-like oxidoreductase.  Notably, mice bearing a double knockout 
of ERO1 and ERO1 (the two mammalian ERO1 genes) are still able to 
generate disulfide bonds in secretory proteins with only a minor delay [175], but a 
triple knockout of ERO1, ERO1, and PRDX4 displays a more severe oxidative 
folding defect [176].  In addition to PRDX4, PDI peroxidases GPX7 and GPX8 
also reduce cytoplasmic H2O2 and may promote disulfide bond formation in the 
ER lumen, although these molecules are relatively under-studied [17, 119].   
Vitamin K-dependent OxidoReductase (VKOR) is another protein that can 
receive reducing equivalents from PDI-like family members.  VKOR is an ER 
transmembrane protein that catalyzes reduction of Vitamin K epoxide to 
hydroquinone (a cytoplasmic co-factor needed for gamma-glutamyl carboxylation 
of newly-synthesized blood clotting factors in the ER (of hepatocytes) [158]), 
allowing the CXXC motif in VKOR itself to become oxidized.  VKOR can then in 
turn receive reducing equivalents from PDI-like oxidoreductases, as shown by 
‘disulfide trap mutants’ of oxidoreductases bearing the active site cysteine 
mutation CXXA that allows for creation/capture of a stable mixed disulfide 
complex with VKOR [141].   
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Quiescin–Sulfhydryl OXidase (QSOX), another source of direct disulfide bond 
oxidation in substrate proteins (in a manner entirely independent of PDI-like 
oxidoreductases), uses molecular oxygen as its terminal electron acceptor to 
very potently generate disulfide bonds directly in substrate proteins (preferentially 
over those in PDI-like family members) and produces H2O2 as a byproduct [49, 
53].  In yeast, the overexpression of QSOX, a monomeric flavoprotein, can 
rescue mutant phenotypes of ero1 null mutants[21].  Yet the physiological role of 
QSOX in mammalian cells remains unknown because of its low expression level 
and its apparent localization in the Golgi complex rather than the ER where most 
secretory protein disulfide bonds are thought to form [20].   
 
3.2.3 Proper Disulfide Bond Formation in the Secretory Pathway may 
also Include Disulfide Reduction and Isomerization   
 
Even after disulfide bond formation in the secretory pathway, there are times 
when existing disulfide bonds must be broken within the ER (or periplasmic 
space of bacteria).  For example, initial disulfide bond formation may involve 
cysteine mispairing, leading an exportable protein into a non-native ‘off-pathway’ 
conformation.  Such mispaired disulfide bonds need either to be broken 
(reduced) or isomerized to native pairings.  In higher eukaryotes, the large 
number of distinct PDI-like oxidoreductases makes it all the more likely that 
subspecialization exists among family members to function more as oxidases or 
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more as reductases for specific substrates — even as all members must cycle 
their catalytic CXXC motifs between oxidized and reduced states.  While this is 
largely unproven in higher eukaryotes, it is plausible that evolution may have 
divided catalysts of disulfide bond formation versus disulfide reduction or 
isomerization into distinct gene products, since such specialization might allow 
for greater functionality.  Even in bacteria, isomerization activity is carried out by 
DsbC and DsbD, which tend not to assist in initial disulfide bond formation within 
substrates [107, 129].  
PDI — which is certainly associated with disulfide bond formation in yeast as well 
as ER reoxidation after reductive stress in higher eukaryotic cells [5] — can also 
be clearly shown to exhibit disulfide isomerase activity.  Indeed, disulfide 
isomerization catalyzed by PDI was one of the observed activities reported by 
Anfinsen in his Nobel prize-winning studies of the in vitro refolding of denatured 
ribonuclease [44].  By contrast, there are other agents, like QSOX (and others 
described below) that do not appear capable of reduction or isomerization of 
disulfide bonds in secretory proteins [53, 127] — providing support for the notion 
of specialization of enzymes in the secretory pathway primarily dedicated to 
substrate oxidation rather than isomerization or reduction.   
 
3.2.4 The Family of PDI-like ER Oxidoreductases   
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As PDI is a prototypic ER oxidoreductase, it is worth briefly reviewing its 
structure-function relationships.  A 55 kDa protein containing two catalytic 
thioredoxin (a and a’) domains, PDI also contains two non-catalytic (b and b’) 
domains arranged as a-b-b’-a’ (Figure 2c) [41, 77, 152].  The non-catalytic b and 
b’ domain (and its following linker region) tend to contain hydrophobic pockets 
that contribute importantly to low affinity binding of a wide variety of substrates 
[47].  The low affinity allows PDI to “sample” many potential substrates and 
thereby to potentially direct rapid catalysis — within the ER, the apparent Km of 
the enzyme for a given substrate is at least as much about protein sampling as it 
is about catalytic activity.  The a and a’ domains may also contribute to substrate 
recognition [47, 152].  PDI and many other members of the PDI-like family of ER 
oxidoreductases also contain the 4 amino acid carboxyl-terminal KDEL-like 
sequence that functions as a Golgi retrieval signal to enrich these proteins within 
the ER.  With the combination of its four domains, PDI can also function as a 
molecular chaperone — preventing aggregation of proteins — in addition to its 
function as an enzyme.  In yeast, catalytically-dead PDI rescues the lethal PDI 
null phenotype, suggesting that PDI’s essential role in the ER goes beyond its 
role in disulfide bond formation [81].  Thus, it is thought that through both its 
catalytic and non-catalytic activities, PDI can minimize kinetic traps — helping to 
eliminate ‘dead-end’ folding intermediates[103, 159].   
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Other PDI-like family members differ in length and activity, but share the common 
thioredoxin-like fold, being grouped on the basis of their content of a, a’, b or b’ 
homology domains. The non-catalytic b and b’ domains are often not well 
defined; moreover, some PDI-like family members are entirely non-catalytic as 
they contain no “a-domain” bearing a CXXC motif (a Ser residue is often found to 
be substituted in place of Cys) — nevertheless, these family members assist in 
protein folding of substrates [136].  For a list of PDI-like ER oxidoreductases, 
please see Table I.  This broad family of PDI-like ER oxidoreductases displays a 
diversity of functions that continues to be discovered.  As a complete review of all 
family members and their putative functions is beyond the scope of this thesis, I 
will cite only a few limited examples.  ERp57, like PDI, has structural units that 
include two redox-active a and a’ domains [48].  However for ERp57, the non-
catalytic b domain contains no substrate-binding hydrophobic pocket [76].  
Instead, the positively-charged non-catalytic domain of ERp57 appears to be 
specialized for interaction with the negatively-charged tip of the P-domain of 
lectin-like chaperones calreticulin and calnexin — it is for this reason that ERp57 
substrates are almost exclusively comprised of glycoproteins [66, 76].  ERdj5 has 
been shown to function mainly as a reductase, breaking disulfide bonds in 
misfolded proteins [154].  ERp72 can act on the same protein substrates as PDI, 
yet ERp72 does not have an identified hydrophobic domain, and its phenotypic 
effects tend to be opposite to those of PDI.  In one such example, PDI has been 
found to act as an unfoldase that enhances the retrotranslocation of cholera toxin 
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from the ER lumen to the cytosol, whereas ERp72 limits cholera toxin 
retrotranslocation [38].  ERp72 and another PDI-like oxidoreductase, P5, have 
been found to complex with the molecular chaperone BiP (GRP78) and may also 
be involved in recognition of misfolded protein cargo [67].  PDILT (PDI-Like 
Testis, restricted to testis) and PDIp (PDI Pancreas, restricted to pancreas) 
interact with endogenous substrates specific to those tissues [31, 48, 156].  
Overall, existing results tend to support the view that different ER 
oxidoreductases are selective about their choice of substrates — the central 
issues (besides cell type-specific gene expression) include their relative 
abundance in the ER, the molecular organization and structure of their catalytic 
and non-catalytic domains, their redox potential (relative ease of reduction vs. 
oxidation of the catalytic CXXC), and the availability of ER resident partner 
proteins for the oxidoreductase that may bring it into close proximity with 
selective substrate proteins.   
 
3.2.5 Selective Activities of Oxidoreductases within the ER 
Environment 
 
While PDI-catalyzed substrate (re-)folding has been extensively characterized in 
vitro, there remains little data on the role(s) of PDI-like oxidoreductases in vivo.  It 
has been reported that siRNA-mediated knockdown of PDI in the HepG2 
hepatocyte cell line results in a modest retardation in oxidative folding of various 
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substrates[133].  The effect is enhanced when combined with simultaneous 
knockdown of other oxidoreductases such as ERp57, resulting in delayed 
substrate exit from the ER — with the authors suggesting functional redundancy 
among members of the PDI-like family of ER oxidoreductases [133].  Conversely, 
it has previously been shown that siRNA-mediated depletion of ERp57 in mouse 
L cells causes a delay in the oxidative folding of MHC class I heavy chain and a 
delay in the export of class I molecules from the ER [173] — and ERp57 
knockout mice die in utero, thought primarily to represent a B cell defect in the 
formation of MHC class I peptide-loading complexes [43].  Thus, it would appear 
that other ER oxidoreductases cannot adequately replace this essential 
physiologic function of ERp57.  Likewise, neither ERp72 nor ERp57 can support 
normal retrotranslocation of cholera toxin A1 polypeptide from the ER to the 
cytosol — a function that appears to be facilitated selectively by PDI [38].  
Indeed, PDI overexpression stimulates ER-Associated Degradation (ERAD, a 
process involving retrotranslocation for proteolysis via the ubiquitin-proteasome 
pathway) of mutant thyroglobulin, while ERp72 overexpression decreases ERAD 
rate for the same mutant [38].  Taken together, these examples suggest that ER 
oxidoreductases exhibit distinct behaviors within the ER.  Nevertheless, multiple 
ER oxidoreductases are induced by ER stress (also known as the Unfolded 
Protein Response, or UPR), and deficiency of a variety of different ER 
oxidoreductases (including ERdj5) can sensitize cells to ER stress-mediated 
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apoptosis [151] — at least in part resulting from deficiency of disulfide reductase 
activity that is needed for the ERAD process [32, 154].  
 
3.2.6 Oxidation of Proinsulin Within the ER  
 
PDI has been well studied with regard to disulfide bond formation within 
proinsulin/insulin, both in vivo and in vitro.  Insulin is comprised of two peptide 
chains (B and A), linked by two disulfide bonds [C(B7)-C(A7), and C(B19)-
C(A20)] (For schematic, please turn to Fig. 1-1).  Proinsulin, the secretory 
polypeptide precursor to biologically active insulin, is a single-chain molecule in 
which the two insulin chains are contiguous because of the presence of the 35 
amino acid connecting peptide plus flanking cleavage sites that is proteolytically 
excised in the final processing events leading to the synthesis of active insulin 
[45].  Thus after cleavage of the signal peptide, the proinsulin primary sequence, 
beginning from the amino-terminus of the molecule, sequentially encodes B-
chain, C-peptide, and A-chain.   
Human proinsulin, produced as an 86 residue peptide (along with a 24 residue 
signal peptide that is cleaved), contains three intramolecular disulfide bonds: the 
two noted above interlink the B- and A-chains while a third is contained entirely 
within the A-chain [C(A6)-C(A11)] [97].  Each of the three bonds is ultimately 
essential to the biological activity of insulin.  In pancreatic beta cells, upon folding 
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to the native state (that includes of course the proper disulfide pairings), 
proinsulin exits the ER and is delivered to the Golgi complex from which newly-
made secretory granules are first formed — the compartment in which 
processing from proinsulin to insulin takes place [55].  Ultimately, the insulin 
granules migrate to the periphery of beta cells to ready themselves for exocytosis 
in response to secretory stimuli such as elevated blood glucose[10].   
The proinsulin gene product is just one member of the large insulin/IGF 
superfamily, each sharing the 3-disulfide structure[90].  Multiple members of this 
family, including both IGF-I and IGF-II, have a branched protein folding pathway 
that can lead to distinct disulfide-linked final structures — including structures 
with fairly similar thermodynamic stability — although only one of these disulfide 
isomers (the native form) has optimal bioactivity [57].   
Quality control in the endoplasmic reticulum, mediated via recognition of non-
native structures by ER chaperones (and oxidoreductases), is designed to limit 
ER export of secretory protein substrates that are biologically inactive due to 
conformational immaturity (i.e., ‘unfolded’) or from having formed inappropriate 
‘dead-end’ folding products (i.e., ‘misfolded’).  In this regard, the three disulfide 
bonds of proinsulin are not equal in importance.  Specifically, without the C(B19)-
C(A20) interchain disulfide bond, proinsulin is incompetent for export from the 
ER, indicating recognition and retention of the “open structure” by ER quality 
control mechanisms [162].  Likewise, absence of the C(B7)-C(A7) interchain 
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disulfide bond both impairs thermodynamic stability and dramatically decreases 
secretability[98, 125].  However, selective absence of the intrachain C(A6)-
C(A11) disulfide bond creates only a modest structural perturbation of proinsulin 
(or insulin) and does not impair secretion [99].   
Not only does improper disulfide bond formation critically perturb insulin function, 
it also appears linked to a chain of events that leads to full-blown diabetes with 
loss of pancreatic beta cell survival.  This is quite a curious situation, as complete 
deletion of up to three of the four wild-type proinsulin-encoding alleles from the 
mouse genome (or loss of expression of one of the two wild-type alleles from the 
human genome) does not cause diabetes or beta cell death [97].  However, the 
presence of mutant proinsulins bearing cysteine substitutions inexorably leads to 
this autosomal-dominant phenotype.  An interesting structural feature of wildtype 
proinsulin is that the C(B7)-C(A7) disulfide bond is nearly exposed at the surface 
of the molecule [58, 169] potentially rendering it susceptible to persistent thiol 
attack.  In fact, recent evidence suggests that the presence of “Akita proinsulin”, 
a mouse mutant bearing the C(A7)Y substitution, blocks the secretion of co-
expressed wild-type proinsulin and results in the production of aberrant disulfide-
linked protein complexes in the ER that contain both wild-type and mutant gene 
products [97].  Moreover, studies of certain additional proinsulin coding sequence 
mutations (including those altering residues other than the cysteines 
themselves), leading to the syndrome of “Mutant INS-gene induced Diabetes of 
Youth” (MIDY), also result in improper disulfide bond formation that triggers the 
 72 
 
same diabetes phenotype as that seen in the Akita mouse [96].  These findings 
validate a sensitive role of proper disulfide bond formation not only for the 
substrate itself, but also for innocent bystander proteins that may come under 
attack by co-expressed proteins that bear reactive cysteine thiols [97].  It is 
believed that proinsulin dimerizes in the ER [64]; what remains to be established 
is whether misfolded proinsulin triggering dominant negative blockade of 
innocent bystander substrates is restricted exclusively to bystander proinsulin or 
may also impact — either through inappropriate mixed-disulfide bonds or via a 
generalized ER stress response — on any other cysteine-bearing secretory 
proteins that happen to be co-expressed in the same ER.   
PDI can catalyze the formation of proinsulin disulfide bonds in vitro [166], yet the 
physiological role of PDI in the ER of pancreatic beta cells remains unknown.  
There are data that do not support the notion of PDI as a facilitator of the 
oxidative maturation of proinsulin in pancreatic beta cells.  Specifically, 
overexpression of PDI in beta cell lines results in a decrease in insulin content 
and secretion, while proinsulin accumulates intracellularly (presumably in the ER) 
[171].  While it is possible that PDI overexpression can result in non-specific 
effects, the results imply an apparent PDI-mediated inhibition of proinsulin export 
from the ER, which in turn suggests a probable defect in the proinsulin folding 
process.  ERO1-Beta has been reported to function as the primary oxidoreductin 
in pancreatic beta cells [175], and, as described in detail above, ERO1 accepts 
reducing equivalents from PDI (and some other PDI-like family members [5]) to 
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allow the ER oxidoreductases to form a catalytic disulfide bond that can be 
transferred to exportable protein substrates.  Impaired expression of the ERO1-
Beta gene produces a phenotype — both in mouse islets and in cultured 
pancreatic beta cells — similar to that seen upon PDI overexpression, i.e., there 
is a delay in ER exit of proinsulin with lower beta cell insulin content and lower 
insulin secretion [70, 175].  Unlike in yeast, knockdown or deletion of PDI gene 
expression is not lethal in higher eukaryotic cells — undoubtedly because of the 
presence of many other PDI-like family members that can partially or fully replace 
its function [133].  Thus, based on the foregoing discussion, PDI knockdown in 
pancreatic beta cells is perfectly feasible, and can be used to directly examine 
PDI effects on proinsulin disulfide bond formation.   
 
3.3  Results 
 
3.3.1 PDI & WT-Proinsulin interaction 
 
In the case of genetic deficiency of ERO1-Beta — at least in part as a 
consequence of incomplete proinsulin thiol oxidation — insulin production and 
consequent insulin secretion is diminished [70, 175].  If proinsulin oxidation from 
ERO1-Beta is mediated by PDI, then loss of PDI expression would be expected 
to phenocopy ERO1-Beta knockdown.  I therefore examined the effect of ERO1-
Beta or PDI knockdown (PDI-KD) in Ins-1 (mouse) beta-cells.  I monitored the 
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recovery of newly-synthesized native proinsulin (nonreducing conditions) relative 
to total proinsulin (reducing conditions) as analyzed by Tris-tricine-urea-SDS-
PAGE  after pulse-labeling cells for 15 min.  As expected (15), ERO1-Beta 
knockdown decreased initial oxidation of proinsulin to the native monomer (Fig. 
3-3 left) by about 20%.  In contrast, PDI-KD did not perturb proinsulin oxidation 
but actually augmented native proinsulin (Fig. 3-3 right).  Importantly, PDI-KD did 
not result in upregulation of other beta cell ER oxidoreductases (Fig. 3-4) 
Moreover, PDI-KD in INS1 cells did not upregulate levels of ER molecular 
chaperones BiP and GRP94, nor activate net phosphorylation of eIF2alpha (Fig. 
3-4) or activate splicing of XBP1 (unlike thapsigargin treatment, Fig. 3-4) extra 
lane).  Thus, there was no discernible evidence that PDI-KD triggers ER stress in 
β-cells.  Furthermore, overexpression of PDI in Min6, a mouse derived pancreatic 
beta cell line, lead to reduction of the recovery of newly-synthesized native 
proinsulin, consistent with results seen with knockdown (Fig. 3-5). 
The perturbation of proinsulin oxidation upon ERO-1Beta knockdown (Fig. 3-3) is 
accompanied by inefficient proinsulin transport through the secretory pathway 
with decreased insulin production [70, 175]. However, by pulse-chase analysis 
after PDI-KD, I actually observed faster maturation of newly-synthesized 
proinsulin (Fig. 3-6, left) with an increased insulin:proinsulin ratio at 1 h chase 
(Fig. 3-6, right). To estimate the consequences of this acceleration on the steady 
state distribution of proinsulin+insulin in INS cells incubated at either 11 or 25 
mM glucose, I found by RIA that PDI-KD shifted the distribution from cells to 
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media (Fig. 3-7). Upon steady-state radiolabeling, I found that most of the insulin 
immunoreactivity secreted from PDI-KD cells was mature insulin, i.e., molecules 
that had exited the ER and were processed in secretory granules (Data not 
shown). This was further observed in Ins832/13 cell that are engineered to stably 
expresses human proinsulin, which becomes processed into human insulin (Fig. 
3-8). To exclude that enhanced secretion was mediated by PDI-KD altering 
prohormone convertase activity, I examined effects of PDI-KD on recombinant 
proinsulin trafficking in 293 cells that have no secretory granules or processing 
enzymes.  By pulse-chase, PDI-KD still led to accelerated secretion (Fig. 3-9, 
top), and shifted the steady-state distribution of proinsulin from cells to media 
(Fig. 3-10, top).  
The experiments were repeated in HepG2 cells (in which PDI knockdown 
perturbs the oxidation and ER exit of several proteins, including albumin, 
transferrin, α-fetoprotein, and α2-HS glycoprotein [133].) with similar positive 
effects for proinsulin to those observed in INS1 and 293 cells (Fig. 3-9, bottom, 
Fig. 3-10, bottom).  In INS1 cells, PDI-KD did not accelerate acquisition of Golgi 
glycosylation of recombinant alpha1-antitrypsin (AAT) (Fig. 3-11).  Moreover, 
PDI-KD did not affect the steady-state levels of processed versus unprocessed 
IAPP (Fig. 3-12, left) nor IAPP secretion over 72 h at low or high glucose (Fig. 3-
12 right).  Thus PDI exhibits selective retention activity for endogenous proinsulin 
in the ER of pancreatic beta-cells and recombinant proinsulin in the ER of 
heterologous cell types.  
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Given the specificity of PDI effects on proinsulin, a possible direct effect of PDI 
on proinsulin was investigated.  Mutations in both A and A’ thioredoxin domains 
(CHGC to SHGS) were found to eliminate the ability of overexpressed PDI to 
prolong the intracellular retention of proinsulin in pancreatic beta cells [171], and I 
obtained similar results for recombinant proinsulin in 293 cells (Fig. 3-13). 
(Interestingly, mutations in key residues of the peptide binding region of PDI (B’, 
F258W, I272A) [73, 122] did not impair the ability of PDI to retain proinsulin in the 
ER). I also attempted siRNA-mediated knockdown of PDI in 293 cells with 
“rescue” using expression of a siRNA-resistant (mouse) PDI.  Catalytically-dead 
PDI (A and A’ mutant) was unable to restore proinsulin intracellular retention, 
while the WT PDI was able to do so (Fig.3-14).  This indicates that the catalytic 
activity of PDI, even at physiologic levels of expression, is likely to be important 
for retaining proinsulin within the ER.   
The catalytic interaction of PDI for proinsulin appeared more consistent with a 
model in which PDI displayed unfoldase activity, as the knockdown of PDI 
appeared to accelerate, as opposed to perturbing, the oxidation of proinsulin. In 
order to further investigate this, I decided to test the ability of individual domains 
of PDI to retain proinsulin. Kulp et al have described the A’ domain as the 
oxidase domain of PDI, and the A domain as the reductase domain [79].  This is 
consistent with a model in which the A’ domain that receives oxidative 
equivalents from ERO-1[6, 7, 79]  In my experiments, the PDI A’ domain mutant, 
in which the A’ CXXC motif is mutated to AXXA (while the A domain remains 
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intact) was able to retain proinsulin at similar levels to the wild-type PDI (Fig. 3-
15, top right). Mutating the A domain, on the other hand, eliminated the ability of 
PDI to cause efficient retention of proinsulin in the secretory pathway (Fig. 3-15, 
bottom right). Although it is unclear whether these mutations impact on the 
physical structure of PDI, these findings appear to be supportive of a mechanism 
in which a reduced (domain) of PDI facilitates its retention, slowing its oxidative 
folding and ER exit. 
As my data indicated a potential PDI/proinsulin interaction occurred via the A 
domain of PDI, a PDI “Trap” mutant, in which the C-terminal cysteine in the 
CXXC motif of the A domain was mutated to alanine, was used to probe a direct 
PDI –proinsulin interaction in pancreatic beta cells. A flag-tagged PDI bearing an 
A domain Trap mutation was expressed in Min6 cells.  At 72 hours post-
transfection, cells were labeled with 500 uCi 35S-cysteine/ methionine in a 60 cm 
dish for 20 minutes.  The cells were then washed once with ice cold Hanks Buffer 
solution supplemented with 20 mM NEM, lysed, and then split into two samples.  
One half was immunoprecipitated with anti-insulin antibodies, while the other half 
was Immunoprecipitated with anti-FLAG antibody overnight. The samples were 
analyzed under both reducing and non-reducing conditions using 4-12% gradient 
SDS-PAGE, followed by autoradiography.  
PDI-TRAP was found to co-precipitate endogenous proinsulin, whereas the PDI 
catalytically-dead mutant could not (Fig. 3-16).  WT-PDI also co-precipitated 
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proinsulin, but to a lesser extent than PDI-TRAP, suggesting a more transient 
interaction between WT-PDI and proinsulin.  Under nonreducing conditions, the 
co-precipitated proinsulin monomer band could not be detected upon FLAG IP, 
but instead a higher molecular weight adduct appeared above the PDI-TRAP 
band, consistent with a mixed disulfide between PDI-TRAP and proinsulin 
(Proinsulin is approximately 8 KD, and PDI-TRAP is 56 KD; thus the adduct band 
appears to be the correct molecular mass of one proinsulin bound to one PDI-
TRAP).  This adduct band is also formed by WT-PDI, but to a lesser extent than 
for PDI-TRAP —although the band was not at all observed in the presence of 
catalytically dead PDI, or in untransfected controls.  By insulin IP, I confirmed that 
proinsulin synthesis was the same in all samples; thus the interaction seen 
between newly-synthesized proinsulin and PDI-TRAP was not due to differences 
in proinsulin synthesis in the different samples.  The conclusion from this 
experiment is that proinsulin in-vivo has the potential to interact with PDI via its 
catalytic domain. This is the first time in a mammalian cell culture based system 
such a potential interaction has been demonstrated.  
 
3.3.2  ERp72 & WT-Proinsulin Interaction 
 
To look for other potential ER oxidoreductases that may assist in the oxidation of 
proinsulin, I set out to quantify mRNA levels for all currently known ER 
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oxidoreductases expressed in pancreatic beta cells.  I did this by designing 
qPCR primers for each of the ER oxidoreductases (http://www.roche-applied 
science.com/sis/rtpcr/upl/index.jsp?id=UP030000).  The primers were then 
validated by performing serial dilutions of 1x, 10x, and 100x cDNAs (in this case, 
from Min 6 cells) and plotting cycle threshold values (CT) against the amount of 
input cDNA, with primer efficiency measured as the slope of the line.  Primers 
used for each of the ER oxidoreductases had a primer efficiency  ≥95%. (Several 
had to be redesigned in order to achieve this).  I then explored two methods and 
found that the second, widely-reported method [70] comparing relative mRNA 
expression levels between genes calculated from CT values obtained with 
validated primers yielded results equivalent to those found in public databases 
(Fig. 3-17A, 3-17B).  Using this method, the data indicated that PDI is among the 
most abundant beta cell oxidoreductase-related mRNA (Fig 3-17B).  P5, ERp57, 
ERP72, represent the next three most abundant oxidoreductase-related mRNAs 
in beta cells.  PDIp, Agr2, Agr3, PDILT, and ERp27 are not expressed.  ERO1-
Alpha is also expressed in beta cells, but its mRNA are found at lower levels, 
consistent with published results [70]. The transmembrane proteins (TMXs), 
appear to be expressed at low levels as well except for TMX2.   
Responsiveness to high glucose was also used as a parameter for suggesting 
oxidoreductases that might be involved in proinsulin folding. Proinsulin translation 
(and later, transcription) increase under high glucose conditions which may 
require a commensurate increase in the synthesis of folding factor(s) that assist 
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in the formation of proinsulin’s three disulfide bonds.  Min6 cells were grown at 
11 mM glucose for 24 hours.  The media were then changed and cells were 
grown further for 48 hours at 11 mM glucose or 25 mM glucose.  cDNA was then 
obtained from replicates under each condition.   
The results indicate that the mRNAs of ERO-1Beta, PDI, ERp72, P5, ER72, (five 
of the most abundant ER oxidoreductase-related mRNAs found in beta cells) are 
upregulated by glucose (Fig. 3-18).  PDIr mRNA was also upregulated with 
glucose (and this mRNA has also been reported to be found at relatively high 
levels according to the Unigene database).  The mRNAs of ERdj5, TMX3, 
ERp44, and ERO-1alpha, which happen to be at the low end of the expression 
spectrum, appear to decrease in response to glucose. The high abundance of 
ERO-1Beta, PDI, ERp72, P5, ER72, and PDIr, and their upregulation with 
glucose, may be indication of their importance to proinsulin biology, possibly in 
the assistance of creating proinsulin’s three disulfide bonds.  
To explore this observation further, the experiment was repeated once with 
cDNA isolated from islets (in this case, 2.8 mM glucose was chosen for low 
glucose, 11 mM for high glucose) and a few selected genes were chosen to be 
examined.  The data were generally consistent with what was seen from Min6 
cells: the mRNAs of PDI, ERP72, P5, and ERp57 all increase upon incubation in 
high glucose (Fig. 3-18).  ERO-1Beta mRNA also increases, to an even greater 
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degree than that observed in Min6 cells (300% in islets vs 35% in Min 6 Cells).  
ERO-1Alpha mRNA levels decreased, as in Min6 cells.  
Due to limited amount of time and resources, I decided to focus on one particular 
ER oxidoreductase to further characterize, specifically targeting an enzyme 
involved in the oxidation of proinsulin’s disulfide bonds. Data from our 
collaborator, Dr. D. Stoffers (U. Pennsylvania), indicated that ERp72 was 
positively regulated by the transcription factor PDX-1 (Pancreatic and duodenal 
homeobox-1), a master regulator of key genes involved in the differentiation of 
pancreatic beta cells (including ERO-1Beta).  In human islets, they found that 
ERp72 was the only ER lumenal oxidoreductase upregulated by PDX-1 (Table 
2).  Given that ERp72 is among the most abundant oxidoreductases, upregulated 
by glucose and by PDX-1, I chose to study it further.  ERp72 has also previously 
been shown to interact with proinsulin in-vitro, but in a context that facilitates 
reduction of proinsulin disulfide bonds rather than oxidation [101, 132, 137, 157].  
To investigate the effects of ERp72 on the folding of proinsulin, I used the same 
assay comparing native proinsulin recovered under nonreducing conditions to 
total proinsulin recovered under reduced conditions, at 48 hours after siRNA 
transfection to obtain ERp72-knockdown.  As with ERO-1Beta knockdown, in 
ERp72-KD cells, there was decreased recovery of the native proinsulin band 
(Fig. 3-19).  I then assayed for proinsulin to insulin maturation as a measure of 
proinsulin export through the secretory pathway.  ERp72-KD cells exhibited 
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slowing of proinsulin to insulin maturation (Fig. 3-20), suggesting impaired 
transport. This phenotype appeared strikingly similar to that seen with ERO-
1Beta knockdown [175]. ERp72-KD displayed no effect on AAT, indicating that 
the general secretory pathway was unaffected with a reduction in ERp-72 
protein. (Fig. 3-21). Finally, using RIA in ERp72-KD cells, I observed a reduction 
in both intracellular and extracellular total insulin levels (50% and 30%, 
respectively) (Fig 3-22).  These results were further confirmed via Western 
blotting, which displayed a significant decrease in both proinsulin and insulin 
levels (Data not shown) 
 
3.4  Discussion 
 
While it is widely assumed that PDI participates in oxidation of proinsulin disulfide 
bonds, which in turn facilitates proinsulin export, I have found instead that PDI 
functions as an ER retention factor for proinsulin in pancreatic beta cells. The 
evidence for this is that in PDI-KD cells, proinsulin transit along the secretory 
pathway is accelerated as measured by pulse-chase experiment, and with a net 
increase in efficiency of total insulin secretion as measured by RIA.  While it is 
conceivable that compensatory changes in gene expression — especially that of 
other ER oxidoreductases — could account for the enhanced proinsulin export, 
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there are no discernible changes in protein levels of other major ER 
oxidoreductases (ERp72, P5, or ERp57) in PDI-KD cells.   
The argument is compelling that proinsulin egress from the ER is linked to the 
kinetics and efficiency of proinsulin disulfide bond formation — especially since 
loss of ERO1-Beta activity is linked not only to decreased efficiency of formation 
of proinsulin’s three native disulfide bonds [ [70, 175] and this report] but is also 
linked to inefficient export of newly-synthesized proinsulin, with delayed and 
decreased production of newly-synthesized insulin [175].  Given the current 
finding that in PDI-KD beta cells, native proinsulin disulfide bond formation is not 
impaired, it seems safe to surmise that PDI is not the primary oxidase 
responsible for receiving reducing equivalents from proinsulin’s cysteine thiols.   
My findings do not preclude the possibility that PDI could help to oxidize 
secretory protein substrates in other cell types [133] or other secretory proteins in 
beta cells under certain environmental conditions.  Even proinsulin can be 
oxidized by PDI, based on reconstitution in vitro [166] .  Nevertheless, it seems 
plausible that in the ER of beta-cells, the net effect of PDI activity may act as an 
unfoldase for proinsulin, thereby lengthening its ER residence time.  Substrate 
unfolding has been implicated in the activity of PDI to promote polypeptide 
retrotranslocation for ER-associated degradation of selected substrates [153] , 
which may include proinsulin [71].  PDI-mediated unfoldase activity for proinsulin 
could account for diminished insulin production and induction of ER stress upon 
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increased expression of PDI in beta cells [171].  Data from 293 results have 
shown that only a small fraction of PDI molecules are fully oxidized, with 80% of 
PDI molecules at least partially reduced, a majority consisting of the A domain of 
PDI in a reduced state [111]. My preliminary data has shown a high proportion of 
reduced/partially reduced PDI in pancreatic beta cells (Data not shown).  This 
can certainly facilitate the ability of PDI to act as unfoldase. Currently, there is no 
evidence that knockdown of PDI leads to either proinsulin misfolding or 
generalized protein misfolding in INS1 beta cells.  Indeed, there is no net 
increase in phosphorylation of eIF2-alpha, no increased splicing of XBP1, and no 
increase of the hsp70 and hsp90 family members of the ER (BiP and GRP94).  
Thus, all evidence points to the idea that PDI-KD in beta-cells is nontoxic.   
On the other hand, in ERp72-KD cells, across several experiments, I observed 
phenotypes of reduced intracellular insulin content, lower insulin secretion, and 
slowing of proinsulin to insulin maturation.  Thus it appears ERp72-KD faithfully 
recapitulates the ERO-1Beta-KD phenotype.  Additionally, ERp72 is among the 
most abundant of the ER oxidoreductase-related mRNAs expressed in 
pancreatic beta cells (like ERO-1Beta), upregulated by glucose (like ERO-1Beta), 
and upregulated by PDX-1 (like ERO-1Beta).  I conclude that, similar to ERO-
1Beta, ERp72 is a candidate oxidoreductase in the pathway of formation of 
proinsulin’s three disulfide bonds.   
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3.5  Methods 
 
Materials — Anti-PDI was from Dr. P. Kim (U. Cincinnati) and from StressGen; 
anti-IAPP from Dr. B. Verchere (U. British Columbia); anti-KDEL from Stressgen; 
anti-ERp72 from Enzo Life Sciences; anti-P5 from Thermo Scientific, anti-ERp57 
from Dr. D. Williams (U. Toronto), anti-phospho-eIF2 alpha from Cell Signaling; 
anti-alpha-tubulin from Sigma; guinea pig anti-insulin was from Millipore.  Wild-
type human AAT cDNA in pCDNA3 was from Dr. R. Sifers (Baylor College of 
Medicine); rabbit anti-AAT was from DAKO.   
Cell Culture and Transfection — Min6 and 293 cells were grown in DMEM 
(containing 4.5 g/L D-glucose, 2.5 mM L-glutamine, and 110 mg/L sodium 
pyruvate) plus 10% FBS and Pen/Strep; Min6 medium was supplemented with 
140 Beta-M 2-mercaptoethanol.  INS1 cells were grown in RPMI-1640 
supplemented with 10% FBS, Pen/Strep and 28 Beta-2-mercaptoethanol.  
PDI, ERO-1Beta, and ERp72 knockdown in INS1 and 293 cells employed 
transfection with 40 nM siRNA using RNAiMax lipofectamine reagent 
(Invitrogen); plasmid transfection in these cells used Lipofectamine 2000 
(Invitrogen) — both following the manufacturer's instructions.  The sequences of 
PDI siRNA oligos were as follows: for INS1, AUAGAACUCCACCAGCAGGTT, 
GCGCAUACUUGAGUUCUUUTT; for 293, GACCUCCCCUUCAAAGUUGUU, 
CCGACA GGACGGUCAUUGAUUACAA. ERO-1Beta, Ins-1: 
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GCGCUCAAUUGUUGATCUU, GCAUCUUUCAGGAUACAAA. ERp72: 
CCAGGACCCAGGAAGAAAU, GCCCUGAAAUAGCCAAGUU.  For experiments 
involving silencing of Ero1-Beta and PDI in Min6, 2 x 106 were nucleofected 
using program G-016 as per the manufacturer’s instructions (AMAXA). Cells 
were nucleofected with 1 nmol of ON-TARGET plus nontargeting  siRNA pool or 
1 nmol of Ero1-Beta ON-TARGET plus SMARTpool (Dharmacon). For PDI 
knockdown, 1 nmol of siRNA was nucleofected into Min6 cells using the same 
combination of oligos used for PDI knockdown in INS1 Cells.  siRNA duplex 
controls for GFP or Luciferase knockdown were from Invitrogen.   
Metabolic Labeling — At 72 h post-transfection, cells were labeled with 100 uCi 
35S-Cys/Met (MP Biomedical) in Cys/Met-free DMEM.  When indicated, cells 
were washed and incubated with 10 mM N-ethylmalemide in ice-cold PBS; then 
lysed in 1% NP-40, 0.1% SDS, 150 mM NaCl, 2 mM EDTA, 10 mM Tris-HCl (pH 
7.4) containing 10 mM NEM and a protease inhibitor cocktail. Lysates were 
immunoprecipitated overnight with anti-insulin, boiled in SDS sample buffer ± 0.1 
M DTT, and analyzed by Tris-tricine-urea-SDS-PAGE.   
RIA and ELISA — An RIA that detects proinsulin+insulin of all species (Millipore) 
was used in all experiments. Media were collected for 24 h at which time total 
insulin levels were assessed in cell lysates and media.  Secretion of IAPP was 
measured by ELISA cross-reacting with rat IAPP (Millipore).   
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Statistical Analysis — Data are presented as mean value +/- s.d.. Statistical 
significance was analyzed by the student's T-Test; a p-value < 0.05 was deemed 
statistically significant.   
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3.6 Figures 
 
  
Figure 3-1.  Oxidoreductase-catalyzed disulfide bond formation.  
 In this diagram, the ER oxidoreductase (oval) oxidizes a secretory protein 
substrate (shown schematically, as a line, at left). In the first step, a sulfhydryl 
group in the substrate attacks a disulfide bond in the thioredoxin motif (CXXC) 
within the oxidoreductase, creating a transient mixed disulfide bond between the 
two proteins.  In the second step, folding changes in the substrate bring another 
cysteine sulfhydryl moiety into proximity with the mixed disulfide.  The 
nucleophilic attack results in the formation of an intramolecular disulfide bond, 
creating a disulfide loop structure within the substrate, and leaving the CXXC 
motif of the oxidoreductase as reduced thiols (electrons represented by dots). 
This will require reoxidation in order that another round of catalyzed disulfide 
bond formation may proceed.   
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Figure 3-1. Oxidoreductase-catalyzed disulfide bond reduction.  
In the first step, the C-terminus cysteine of a sulfhydryl group, in the thioredoxin 
motif in an oxidoreductase, attacks a disulfide bond in within the substrate, 
creating a transient mixed disulfide bond between the two proteins.  In the 
second step, nucleophilic attack  by a sulfhydryl group the N-terminus cysteine 
on the mixed disulfide leads to the oxidation and formation of a disulfide within 
thioredoxin domain of the oxidoreductase. The substrate now is (partially) 
reduced.  Note, mutation of the N-terminus cysteine negates the ability of the 
mixed disulfide from being resolved, which becomes “trapped” in this 
conformation. 
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Figure 3-1. Oxidoreductase-catalyzed disulfide bond isomerization.  
The process of isomerization begins similar to the process of reduction, with the 
C-terminus cysteine of a sulfhydryl group in the thioredoxin motif in an 
oxidoreductase attacking a disulfide bond within the substrate, creating a 
transient mixed disulfide bond between the two proteins. However unlike in the 
reduction reaction, where the mixed disulfide is resolved by attack by the 
sulfhydryl from the N-terminus cysteine in the thioredoxin motif, the now free 
sulfhydryl group in the substrate attacks another intramolecular disulfide bond 
within the substrate, leaving the sulfhrdyl group on the remaining unpaired 
cysteine to attack the mixed disulfide. This results in a 
rearrangement/isomerization of disulfide bonds within the substrate, with no 
change in the redox status of the oxidoreductase, which remains in the reduced 
state. 
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Figure 3-2. Domain structure of selected ER oxidoreductases.   
Schematic of PDI-like family members, comprising "A"-type thioredoxin domains 
that are catalytically active (shown in gray), and "B"-type non-catalytic  
thioredoxin domains. 
 92 
 
 
Figure 3-3. Recovery of newly synthesized proinsulin with PDI and ERO1 
beta knockdown 
Middle panel: At 48 h post-transfection with either scrambled (Con) or ERO1β or 
PDI siRNA duplexes (20 nM), Ins-1 cells were pulse-labeled for 15 min with 35S-
Cys/Met, and lysed in SDS buffer with 10 mM NEM.  Lysates were 
immunoprecipitated in duplicate with anti-insulin and analyzed by Tris tricine-
urea-SDS-PAGE under reducing (“P" = 100 mM DTT) or nonreducing ("N") 
conditions. Panel above: Western blotting for PDI and ERO1Beta at 48 hours 
post-transfection. Lower panel: Quantitative band densitometry of the Native 
proinsulin disulfide isomer (gel at left band "N") was divided by that for total 
labeled Proinsulin ("P") to calculate the percentage of native form. For ERO-
1Beta-KD, the data are from one experiment conducted in triplicate (N=3). For 
PDI-KD, the data represent five independent experiments (N=10), with an 
average pulse time of eight minutes. The p-Value for PDI-KD was =0.03.  
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Figure 3-4. Measurement of ER Oxidoreductases and Stress Markers. 
INS1 cells treated with siRNA duplexes (100 nM) designed for knockdown of the 
Luciferase mRNA (a negative control, "C1"), GFP mRNA (negative control "C2"), 
or PDI-KD were lysed at 72 h post siRNA transfection.  Upper eight set of bands: 
Western blotting for the antigens indicated, normalized to protein (10 or 20 μg, 
depending on antigen), with -tubulin serving as a loading control.  BiP and 
GRP94 were identified with anti-KDEL antibodies.  Bottom row: XBP1 mRNA 
was measured by RT-PCR using primers that amplify both unspliced ("u") and 
spliced ("s") forms (22).  As a positive control for ER stress, cells were treated 
with thapsigargin (downward arrowhead first lane: 1 M for 3 h). 
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Figure 3-5. Recovery of newly synthesized proinsulin with PDI 
overexpression. 
Left panel: At 48 h post-transfection with PDI plasmid, Ins-1 cells were pulse-
labeled for 15 min with 35S-Cys/Met, and lysed in SDS buffer with 10 mM NEM.  
Lysates were immunoprecipitated in duplicate with anti-insulin and analyzed by 
Tris tricine-urea-SDS-PAGE under reducing or nonreducing conditions. Right 
panel: Quantitative band densitometry of the native proinsulin disulfide isomer 
was divided by that for total labeled to calculate the percentage of native form. 
Data is quantified from panel on the left. 
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Figure 3-6. ER Exit of proinsulin, PDI-KD (Ins-1 Cells). 
At 72 h post transfection with either scrambled (Con) or PDI siRNA ("KD") 
duplexes (100 nM), INS1 cells were pulse-labeled for 20 min with 35S-Cys/Met 
and either lysed immediately or chased for 1 h and both media ("M") and cell 
lysates ("C") collected.  Samples were immunoprecipitated with anti-insulin and 
analyzed by Tris tricine-urea-SDS-PAGE under reducing (100mM DTT) and 
nonreducing conditions. Right panel: Quantitative band densitometry of the 
labeled insulin at 1 h chase was divided by that for labeled proinsulin; in control 
cells this ratio was arbitrarily set to 1.  The labeled insulin/proinsulin ratio in PDI-
KD cells was then compared to that in control cells (p = 0.001). N=5 independent 
experiments. 
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Figure 3-7. Steady-State Measurements of total insulin in Ins-1 cells, PDI-
KD. 
Left Panel. After 48 h post-transfection with either scrambled (light bars) or PDI 
siRNA duplexes (dark bars), the media was changed and fresh media at the 
indicated glucose concentrations applied, and collected for an additional 24 h.  At 
that time, the cells were lysed and total insulin (i.e., insulin plus proinsulin) in both 
cell lysates and media was measured by RIA.  The data are the mean of two 
experiments with 5 independent replicates; control values were set to 100%.  At 
11 mM glucose for cells (control v. PDI-KD) p = 0.001; for media p = 0.01.  At 25 
mM glucose for cells (control v. PDI-KD) p = 0.001; for media p = 0.002. 
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Figure 3-8. Steady-State Measurements of Human Insulin in Ins 832/13 
cells. 
Ins 832/13 cells were transfected with either scrambled (light  bars) or PDI siRNA 
duplexes (dark bars). Media was collected for 24 hour period. Each time point 
represents an individual biological replicate. Processed, human insulin was 
measured via a human-specific insulin RIA that only recognizes processed 
human insulin. The experiment is N=1 for each time point.  Values are 
normalized to total protein.  
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Figure 3-9. PDI-KD effects on enhanced ER export are selective for 
proinsulin as a substrate 
Top panel. At 48 h post-transfection with either scrambled (Con) or PDI siRNA 
duplexes (100 nM), 293 cells were pulse-labeled for 30 min with 35S-Cys/Met and 
chased, with media ("M") collected and cells analyzed ("C") Proinsulin ("Proins") 
was immunoprecipitated with anti-insulin and analyzed by Tris tricine-urea-SDS-
PAGE.  Bottom panel: A similar experiment was performed in HepG2 cells. 
B=Blank lane. 
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Figure 3-10. Steady-State  Levels of Proinsulin, 293 and HepG2 cells. 
After 48 h post-transfection with either scrambled (light bars) or PDI siRNA 
duplexes (dark bars), the media bathing 293 cells was changed and fresh media 
collected between 48 - 72 h.  At that time the cells were lysed and proinsulin in 
both cell lysates and media was measured by RIA. For purposes of 
quantification, the amount of proinsulin recovered in the media was divided by 
the amount recovered in the cells. The control value was arbitrarily set to one.  
Control v. PDI-KD cells, p = 0.007. (Four experiments with 9 independent 
replicates).  For HepG2, cells and media was collected 24- 48 post transfection 
and analyzed as in 293 cells. Control v PDI-KD, p=0.002.  
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Figure 3-11. ER Exit of AAT, PDI-KD. 
INS1 cells were transfected to express 1-antitrypsin (AAT).  The cells were then 
split and treated with either scrambled (Con) or PDI siRNA duplexes (100 nM, 
PDI knockdown was confirmed by Western blotting, not shown).  The cells were 
pulse-labeled for 20 min with 35S-Cys/Met, chased for the times indicated, and 
media collected and cells lysed as in Fig. 1C.  The samples were 
immunoprecipitated with anti-AAT and analyzed by SDS-PAGE.  ER exit was 
evaluated by migration from the ER-glycosylated form of AAT to the Golgi-
glycosylated form 
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Figure 3-12. IAPP Processing, PDI-KD (Ins-1 Cells). 
INS1 cells treated with siRNAs duplexes (100 nM) designed for knockdown of 
Luciferase mRNA ("C1"), GFP mRNA ("C2"), or PDI-KD exactly as in Fig. 1B, for 
72 h.  Left panel: Western blotting for the antigens indicated, normalized to 
protein (10 μg), with -tubulin serving as a loading control.  The result is 
representative of three independent experiments.  Right panel: INS1 cells 
transfected with siRNAs (100 nM) were grown for 3 days in RPMI media at lower 
(11 mM) or higher (20 mM) glucose.  The media were collected, and IAPP 
secretion was analyzed by ELISA (see Experimental Procedures).  
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Figure 3-13. Catalytic domain is required for retention of proinsulin when 
overexpressing PDI. 
After 24 h post-transfection with  either WT PDI, A + A’ , or PDI F258W, I272A (B’ 
mutant) plasmid, the media bathing 293 cells was changed and fresh media 
collected between 24 - 48 h.  At that time the cells were lysed and proinsulin in 
both cell lysates and media was measured by RIA. For purposes of 
quantification, the amount of proinsulin recovered in the media was divided by 
the amount recovered in the cells. The control value was arbitrarily set to one. 
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Figure 3-14a. The catalytic domain of PDI is required to restore the 
retentive function of after knockdown. 
PDI Western.  293 cells were transfected with WT Proinsulin, split, and then 
transfected with PDI or scrambled oligo. Cells were subsequently transfected 
with a plasmid encoding for WT PDI, PDI A and A’ mutant, or in the case of the 
control GFP.  
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Figure 3-14b. The catalytic domain of PDI is required to restore the 
retentive function of after knockdown. 
Samples were analyzed as previously described. Data is from two independent 
experiments conducted in triplicate (N=6). 
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Figure 3-15. The A domain is required for efficient retention of proinsulin by 
PDI. 
Various mutant constructs were transfected into 293 cells and assessed for 
retention of proinsulin as previously described. Each graph represents one 
experiment conducted in duplicate. 
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Figure 3-16. PDI directly interacts with proinsulin via its catalytic domain. 
Min6 cells were transfected with a plasmid encoding for a WT PDI, A and A’ 
mutant PDI, or a Trap  “A (CXXA)” PDI Mutant. Each construct was tagged with a 
FLAG epitope. GFP was transfected into control cells.  At 72 hours post-
transfection, cells were labeled with  500 uCi 35S-cysteine/ methionine in a 60 cm 
dish for 20 minutes.  The cells were washed once with ice cold Hanks Buffer 
solution (with calcium and magnesium chloride) supplemented with 20 mM NEM, 
lysed, and then split into two samples.  One half was immunoprecipitated with 
anti-insulin antibodies, while the other half was Immunoprecipitated with anti-
FLAG antibody overnight. The samples were analyzed under both reducing and 
non-reducing conditions using 4-12% gradient SDS-PAGE, followed by 
autoradiography.  
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Figure 3-17. Quantification of relative transcription levels of ER 
Oxidoreductases  
Mouse pancreatic islets.  The data represent the average of two data sets 
available from Unigene. (http://www.roche-applied 
science.com/sis/rtpcr/upl/index.jsp?id=UP030000, libraries 16013 and 5429.) For 
ER Oxidoreductases not shown, data was unavailable. The value of PDI was 
arbitrarily set to one.  
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Figure 3-17. Expression levels of ER Oxidoreductases. 
Min 6. Reverse transcribed cDNAs were obtained from Min6 cells grown in 
11mM or 25mM growth media for 48 hours. qPCR analysis was performed for 
each ER oxidoreductase. Relative expression levels were obtained using the 
formula, message Level= 2^CT Value. The expression level of ERdj5, the gene 
with lowest level of expression, was arbitrarily set to 1. Note data was not 
assessed for statistical significance. 
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Figure 3-18a. Expression of ER oxidoreductases in response to high 
glucose.  
Min6 cells. Min6 cells were initially grown at 11 mM glucose for 24 hours, then 
changed to 11 mM glucose or 25 mM glucose for 48 hours.  cDNA was then 
obtained from replicates under each condition. The percentage increase = the 
relative amount of message in high glucose/low glucose. The data is 
representative of two experiments, each conducted in duplicate (N=4). 
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Figure 3-18b. Expression of ER oxidoreductases in response to high 
glucose. 
Pancreatic Islets. Reverse transcribed cDNAs were obtained from freshly 
isolated pancreatic islets were grown at either 2.8 mM (low) glucose or 11(high) 
mM glucose for 48 hours. qPCR analysis was performed for each ER 
oxidoreductase. The data is representative of one experiments. (N=1).  
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Figure 3-19. Recovery of newly synthesized proinsulin with ERp72 
knockdown. 
Left panel. At 48 h post-transfection with either scrambled (Con) or ERp72 siRNA 
duplexes (20 nM), Ins-1 cells were pulse-labeled for 15 min with 35S-Cys/Met, 
and lysed in SDS buffer with 10 mM NEM.  Lysates were immunoprecipitated in 
duplicate with anti-insulin and analyzed by Tris tricine-urea-SDS-PAGE under 
reducing or nonreducing ("N") conditions. Right panel. : Quantitative band 
densitometry of the Native proinsulin disulfide isomer (gel at left band "N") was 
divided by that for total labeled Proinsulin ("P") to calculate the percentage of 
native form. The data represent three independent experiments (N=6), p=.0048.  
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Figure 3-20. ER Exit of newly synthesized proinsulin, ERp72-KD. 
At 72 h post transfection with either scrambled (Con) or ERp72 siRNA (“ERp72-
KD") duplexes (100 nM), INS1 cells were pulse-labeled for 20 min with 35S-
Cys/Met and either lysed immediately or chased for 2 h and both media ("M") 
and cell lysates ("C") collected.  Samples were immunoprecipitated with anti-
insulin and analyzed by Tris tricine-urea-SDS-PAGE under nonreducing 
conditions. Right panel: Quantitative band densitometry of the labeled insulin at 2 
h chase was divided by that for labeled proinsulin; in control cells this ratio was 
arbitrarily set to 1.  The labeled insulin/proinsulin ratio in ERp72-KD cells was 
then compared to that in control cells. The calculations are representative of two 
independent experiments.  
   
 113 
 
 
Figure 3-21. ER Exit of AAT, ERp72-KD. 
INS1 cells were transfected to express 1-antitrypsin (AAT).  The cells were then 
split and treated with either scrambled (Con) or ERp72 siRNA duplexes (100 nM, 
ERp72 knockdown was confirmed by Western blotting, not shown).  The cells 
were pulse-labeled for 20 min with 35S-Cys/Met, chased for the times indicated, 
and media collected and cells lysed as in Fig. 1C.  The samples were 
immunoprecipitated with anti-AAT and analyzed by SDS-PAGE.  ER exit was 
evaluated by migration from the ER-glycosylated form of AAT to the Golgi-
glycosylated form.  
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Figure 3-22. Steady-State Measurements of total insulin in Ins-1 cells, 
ERp72-KD. 
After 24 h post-transfection with either scrambled (light bars) or ERp72 siRNA 
duplexes (dark bars), the media was changed and fresh media at the indicated 
glucose concentrations applied, and collected for an additional 24 h.  At that time, 
the cells were lysed and total insulin (i.e., insulin plus proinsulin) in both cell 
lysates and media was measured by RIA.  The data are the mean of three 
experiments with 9 independent replicates; control values were set to 100%.  For 
cells, p=.0048. Media, p=.0045. 
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 Gene 
Name 
Protein Thioredoxin 
Domains 
Catalytic Motif 
Sequence 
1 P4HB PDI 4 (2) CGHC, CGHC 
2 PDIA3 ERp57 4 (2) CGHC, CGHC 
3 PDIA4 ERp72 5 (3) CGHC, CGHC, CGHC 
4 PDIA6 P5 3 (2) CGHC, CGHC 
5 DNAJC10 ERdj5 6 (4) CSHC,  CPPC, CHPC, CGPC 
6 PDIA2 PDIp 4 (2) CGHC, CTGC 
7 PDIA5 PDIr 4 (3) CSMC, CGHC, CPHC 
8 TXNDC12 ERp18 1 (1) CGAC 
9 ERp27 ERp27 2 (0) None 
10 ERp29 ERp29 2 (0) None 
11 ERp44 ERp44 3 (1) CRFS 
12 ERp90 ERp90 5 (0) None 
13 TXNDC5 ERp46 3 (3) CGHC, CGHC, CGHC 
14 PDILT PDILT 4 (2) SKQS*, SKKC 
15 Agr-2 Agr-2 1 (1) CPHS 
16 Agr-3 Agr-3 1 (1) CQYS 
17 TMX1 TMX1 1 (1) CPAC 
18 TMX2 TMX2 1 (1) SDNC 
19 TMX3 TMX3 3 (1) CGHC 
20 TMX4 TMX4 1 (1) CPSC 
21 TMX5 TMX5 1 (1) CRFS 
 
Table 3-2. Mammalian PDI-like family members. 
Gene names (first column) as well as protein alias (second column) are shown.  
The total number of thioredoxin domains in each gene product is indicated, with 
the number of catalytically-active domains listed in parentheses.  The specific 
CXXC sequences are  listed in the last column; note that for PDILT (line 14) the  
SKQS motif bears strong resemblance to the A domain of PDI and is listed under 
the catalytic motif sequence, although it does exhibit catalytic activity.  Family 
members highlighted with gray background signify transmembrane proteins, and 
the first five members in large font denote those whose functions are specifically 
mentioned within the text.  
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Table 3-3. PDX-1 occupancy in Mouse and Human Islets.. 
CHIPseq data of ER Oxidoreductase occupancy using PDX-1 as input. (Data 
provided by Dr. Cythnia Khoo). 
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CHAPTER 4   CONCLUSIONS 
 
Arguably, insulin may be the most important hormone regulator of metabolism.  
The gene family is ancient, and even in modern, highly-evolved organisms, the 
continuous production (and secretion) of insulin, every minute of every day, is 
central to metabolic homeostasis, including actions in the brain, in classical 
insulin-sensitive peripheral tissues, and in the pancreatic islets themselves [88].  
There are few if any cell types in the body that express no insulin receptors.  
Insulin action at a physiological level has major effects not only on blood glucose, 
but also on redistribution of amino acids, and generalized anabolism.    
Insulin is the first protein to be sequenced, and its X-ray crystal structure has 
been studied again and again.  The molecule serves as one of the prototypes in 
studies of protein structure and function, it is a major pharmacological target, and 
virtually every residue of the polypeptide has been individually mutagenized in 
different labs around the world.  The amount of attention surrounding insulin 
comes as no surprise, as its loss leads to devastating metabolic consequences, 
whether it occurs on the first postnatal day or after 50 years of life.  So much is 
known about insulin, yet there are many questions that remain unanswered in 
how and why insulin is manufactured in pancreatic beta cells.   
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Insulin is made as processing intermediates that are consecutively cleaved . First 
the signal peptide is removed as soon as the preproinsulin is translocated into 
the ER.  Then comes the excision of the C-peptide, endoproteolytically removed 
from the middle of the proinsulin molecule as the protein exits the Golgi complex 
and completes its maturation in immature secretory granules.  In between these 
two steps, proinsulin matures into its native conformation. The nascent 
proinsulin, to become active insulin, needs not only to make three disulfide 
bonds, but they specifically must be C(B7)-C(A7), C(B19)-C(A20), and C(A6)-
C(A11).  The overall theme of my thesis project touches on two of these aspects 
of the insulin manufacturing process – the making of the proinsulin disulfide 
bonds, and the endoproteolytic cleavage of proinsulin into insulin.   
In Chapter 2 of my dissertation, I investigated the requirement of endoproteolytic 
cleavage for proinsulin of the C-peptide. Proinsulin is purported to display only 
2% binding to the insulin receptors as processed insulin [149].  While it is unclear 
what  led the evolution (pro)insulin into a pathway requiring cleavage-dependent 
activation, I wondered if it were possible to generate a “proinsulin” that might 
specifically and selectively activate insulin receptors (and not growth factor 
receptors).The idea of a single chain insulin (like) molecule has already been 
conjured up by evolution. IGF-1 and IGF-2 are structurally similar to insulin, being 
secreted from cells and acting on cell surface receptors – and even activating a 
number of common downstream signaling pathways [90].  Yet IGF-1 and IGF-2, 
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and many other members of the larger insulin/IGF superfamily – do not undergo 
endoproteolytic cleavage for purposes of making a bioactive peptide.  
My studies in Chapter 2 were influenced by a paper reporting a Single Chain 
Insulin (SCI) used in gene therapy that was shown to reverse diabetes in rodent 
models [84].  I wanted to see if I could learn any of the primary structural 
principles that would lead to a bioactive SCI, and with this in mind, through 
rational mutagenesis, I created a range of constructs to be tested, in order to 
understand the rules and guidelines that would allow a SCI to exhibit biological 
activity.  I specifically focused on modifying the C-peptide length and amino acid 
content without at all altering the primary structure of the insulin B-chain or A-
chain.  As for specific residues to modify, I focused most of my attention on the 
two flanking residues on the N- and C-terminal ends of the C-peptide, which 
normally represent the dibasic cleavage sites of proinsulin.   
In regards to the size of the linker, the progressive loss of biological activity of 
SCIs as their linker sequences grew to ever greater length (>15) most likely 
reflects an inability of the insulin moiety to make proper contact with insulin 
receptors, resulting in limited activation.  These findings readily explain the low 
bioactivity of proinsulin itself [59], as the intervening C-peptide sequence 
sterically interferes with ligand binding.  At the other end of the spectrum, I found 
that a linker length of five amino acid residues was an absolute minimum in order 
to exhibit biological activity.  Although consistent with published results that 
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demonstrate that a linker length below 5 residues alters the alignment of the B- 
and A- chains of the polypeptide in such a way that the proper disulfide bonding 
no longer occurs [99], it also raises some important questions. Does a small 
linker length limit the ability of the SCI to activate the receptor, or is it the case 
that the limiting factor is the formation of the proper disulfide bonds during 
peptide biosynthesis?   
Perhaps both these mechanisms factor into the inability of pro(insulin) and the 
SCIs from activating the insulin receptor.  It has been reported that a direct 
tethering of the B- and A-chains, even with proper disulfide bonds, does not yield 
a biologically active construct [30]. The presence of a tight turn with a short linker 
between B- and A-chains is likely to seriously restrict the movement of the distal 
B-chain to “side-step” [11] so that the N-terminal portion of the A-chain can make 
proper receptor contact [12].   
In addition to these findings, the amino acids immediately adjacent to the B- and 
A-chain termini appeared to have great impact on the biological activity of SCIs, 
particularly the C-terminal end of the linker, adjacent to the A-Chain.  In all 
constructs, the presence of a basic residue directly preceding the A-Chain was 
required for biological activity.  My data suggested that a single arginyl side chain 
proximal to the A-chain may be an important feature for SCI interaction with 
insulin receptors.  Note that the endoproteolytic processing of proinsulin creates 
a free amino-terminal Gly(A1).  This free amino group appears to be required for 
 121 
 
receptor activation, and in my SCIs, a preceding Arg residue with a charged 
amine side chain is likely to mimic this free amino group that presents itself after 
proinsulin cleavage.  Substitutions at this position with a Lys residue would be a 
useful next step, but in each of my constructs, I worked with Arg because it is the 
evolutionarily conserved residue at this position in proinsulin.   
An additional basic amino acid next the arginyl group adjacent to the A-Chain 
was used by others working on SCIs.  However, dibasic residues raised the 
possibility of potential cleavage which would eliminate the single-chain structure.  
In fact, my experiments conducted in AtT20/PC2 cells that expressed the 
secretory granule endopeptidases (Chapter 2, Figure 2) showed that such 
dibasic residues are in fact cleavable by naturally-occurring endopeptidases of 
the secretory pathway.  For this reason, I worked to create alternative SCIs that 
have no potential to be cleaved.  The –QRGGGGQR- linker peptide between the 
B- and A-chains generated a SCI that exhibits comparable bioactivity to the best 
available, as well as moderately high expression levels (Chapter 2, Table 2).  I 
believe that this construct could have great future utility if gene therapy for 
diabetes (type 1 or 2) continues to advance. 
 
In the course of my studies, I found that the amino acids in the middle of the 
linker peptide somehow affects protein expression level.  For example, the linker 
peptides –RRYGLDVKR- and –RRGGGGGKR- (Lines 19, 20 in Chapter 2, Table 
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1, respectively) result in comparable biological activity on insulin receptors, but 
very different protein expression levels upon biosynthesis (approximately 5-7 fold 
difference in favor of the –RRGGGGGKR- linker).  Thus, although the specific 
amino acid content in middle of the linker appear to be less restrictive in 
comparison to the flanking residues from the vantage point of bioactivity (with the 
only requirement perhaps being a flexible chain to allow the connecting structure 
to make a turn), the impact of these amino acids on expression or stability of 
SCIs warrants further study.  
Finally, in addition to gene therapy, SCIs might have utility as analogs. Although 
not studied, these SCIs might have differences in stability, solubility, and 
clearance from the bloodstream, which is the pharmacological basis for which 
analogs already on the market have been selected as treatments for diabetes.  
From a manufacturing perspective, SCIs also may also be easier to produce 
recombinantly than two-chain insulins (see Chapter 1).    
In Chapter 3 of my dissertation, I turned my attention to the formation of the three 
disulfide bonds of proinsulin.  Each of these three disulfides is absolutely 
required for the biological activity of insulin — just as is the case for the insulin-
like growth factors.  For the IGFs, it is famously known that they form two distinct 
stable disulfide-bonded structures — only one of which is bioactive [57].  Since 
both these structures can be found secreted from cells, evidently the ER quality 
control mechanisms do not sensitively recognize the native state from a 
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conformation that engages all Cys residues in disulfide bonding, but nevertheless 
exhibits mis-pairing.  In my Introduction to Chapter 3, I highlighted that the 
pathways of disulfide bonding in the ER still remain an area of extensive ongoing 
investigation.  A secretory protein may make its way to the native state via 
distinct disulfide intermediates, in which the individual native disulfide bonds may 
form in different sequential order.  It would therefore seem that proinsulin and 
IGFs would be likely substrates both for the actions of ER oxidoreductases acting 
as ‘oxidases’, promoting disulfide bond formation, and as ‘reductases and 
isomerases’, requiring the breakage of at least one disulfide bond after it has 
been made.   
In Chapter 3, I focused my own experiments primarily on two of the most 
abundant ER oxidoreductases of pancreatic beta cells, PDI and ERp72.  With 
regards to PDI, I found that this protein does interact with proinsulin in a manner 
that requires a catalytically active thioredoxin motif in the PDI A-domain.  
Curiously, however, my results unequivocally do not support PDI as a facilitator 
of proinsulin disulfide bond formation.  My hypothesis is that PDI acts as net 
reductase for proinsulin, and this clearly warrants further investigation.   As 
mentioned in the Introduction to Chapter 3, proinsulin is believed to have an 
exposed surface disulfide bond in C(B7)-C(A7).  Thus, even after its formation, 
this disulfide bond may remain susceptible to attack.  Using a PDI-TRAP mutant, 
I was able to recover a mixed disulfide adduct with the endogenous proinsulin of 
pancreatic beta cells.  Moreover, even upon overexpressing WT-PDI, I was still 
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able to detect this adduct, although it was less abundant than with the TRAP 
mutant. This may signify that the mixed disulfide with PDI is rapidly resolved, 
such that steady-state levels of adduct are ordinarily very low.  Conceivably, 
reduced PDI might attack the surface-accessible C(B7)-C(A7) disulfide bond, 
thereby unfolding proinsulin reduced at the B7/A7 positions.  In truth, however, at 
the present state of knowledge we do not yet know where (or when) on proinsulin 
might PDI make its covalent linkage to create a mixed disulfide bond.  In any 
case, I have found that there is a relationship between the catalytic activity of PDI 
and its phenotypic effects to limit the rate of proinsulin egress from the ER. 
Importantly, PDI overexpression results in similar phenotype to that observed 
upon ERO1-Beta knockdown, with both decreased proinsulin export and 
decreased insulin production.  This diminution of proinsulin export is linked to the 
catalytic activity of PDI- especially that contained in the A-domain thioredoxin 
motif, which appears to be involved in reductase activities of PDI [79].   
Preliminary results seem to rule out the intramolecular C(A6)-C(A11) disulfide 
bond as a potential site for PDI interaction.  First, this bond is buried deeply 
within the globular proinsulin protein [64].  Second, the A6/A11 double mutant 
proinsulin has the distinction of escaping the ER with normal kinetics [96].  Third, 
the A6/A11cysteine double mutant proinsulin can also form a structure with the 
same mobility as native proinsulin by nonreducing Tris-tricine-urea-SDS-PAGE, 
strongly suggesting that the B19-A20 and B7-A7 disulfide bonds are intact [98].  
Fourth, transfecting this A6/A11 double cysteine mutant proinsulin construct into 
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293 cells and subsequently knocking down PDI results in increased proinsulin 
secretion (Fig.  4-1). Thus, I believe that ER retention caused by PDI must 
operate either through the C(B7)-C(A7) or C(B19)-C(A20) disulfide bond — 
realizing that the former bond is surface exposed and the latter is buried.   
Finally, my experiments have yielded results consistent with ERp72 as an 
oxidoreductase that could be involved in the formation of proinsulin’s three 
disulfide bonds.  To determine a direct interaction of proinsulin and ERp72 would 
further provide evidence to support this finding, and these experiments are 
currently ongoing.  A “direct interaction” of proinsulin and ERp72 has been 
reported in pancreatic beta cells but to this point, no actual data have been 
published other than immunofluorescence co-localization [37].  I plan to employ a 
similar “trap” mutant of ERp72 similar to that used to study PDI interaction with 
proinsulin.  ERp72 has three CHGC thioredoxin domains, and I have “Trap” 
mutants for all three domains.  However there are caveats that are associated 
with this experiment. By mutating the C-terminal residue of each CXXC motif — 
based on my understanding of how these motifs operate — this essentially 
creates a reduced thioredoxin motif.  This reduced domain would then attack a 
disulfide bond in a substrate, mimicking an initial reductase/isomerase step.  
Although perfect for an oxidoreductase that acts reductase/unfoldase for 
proinsulin, i.e. PDI, I am unclear whether such an experiment is a suitable mimic 
for an oxidoreductase that catalytically transfers one or more disulfide bonds to 
proinsulin.  Thus, on the one hand, I have reservations that the experiment may 
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not be able to isolate ERp72/proinsulin adducts, while on the other am concerned 
with  the interpretation of results even if such adducts are obtained.   
My studies do not rule out the possibility that other ER oxidoreductases may 
participate in the process of proinsulin disulfide bond formation.  I have 
performed a screen of various ER oxidoreductases by siRNA-mediated 
knockdown; and I find that knockdown of several other gene products can 
produce phenotypes with similar directionality to those of ERp72-KD or PDI-KD 
(although at lesser magnitude).  Published results in HepG2 cells have already 
suggested compensation by other ER oxidoreductases when one ER 
oxidoreductase is knocked down [133].  A degree of functional redundancy of 
oxidoreductases would thus not be surprising in pancreatic beta cells.   Another 
future question is whether proinsulin disulfide bond formation might occur without 
ER oxidoreductase-mediated disulfide transfer, i.e., via QSOX, which as pointed 
out in Chapter 3 can catalyze disulfide bond formation in substrate proteins 
without going through an ER oxidoreductase intermediate [75].  
In summary of Chapter 3, my results suggest that ERp72, rather than PDI, 
participates in proinsulin disulfide bond formation in pancreatic beta cells.  The 
role of PDI, which I hypothesize is linked to proinsulin unfolding, could be 
extremely important in the proteasomal degradation of misfolded forms of 
proinsulin.  These findings seem in opposition to some of the work published on 
PDI-proinsulin interactions in-vitro.  However, I believe that the in-vitro conditions 
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show what is possible and may not necessarily recapitulate the biology in the 
context of the ER of living cells.  Indeed, by analogy to what has been described 
previously for the retrotranslocation of cholera toxin from the ER, where PDI and 
ERp72 play opposing roles (PDI favors retrotranslocation; ERp72 limits 
retrotranslocation) [38], the opposing roles of these two major ER 
oxidoreductases could represent a balance that regulates proinsulin anterograde 
trafficking.   
In conclusion, my overall dissertation research has concentrated on two stages 
of proinsulin maturation in the secretory pathway.  In Chapter 2, I have 
contributed to a growing understanding that proinsulin endoproteolytic cleavage 
is likely to be a late evolutionary modification, converting a single-chain ancestral 
hormone into a cleaved, two-chain ligand.  Presumably, insulin and insulin 
receptors evolved in parallel in the development of signaling more specific to 
metabolic control.  I have found however that it is still possible to activate modern 
day insulin receptors with single-chain insulin ligands to bring about favorable 
metabolic effects such as glucose uptake into fat cells and suppression of 
hepatocyte gluconeogenic enzymes.  In Chapter 3, I have contributed to a 
growing understanding that the making of the three evolutionarily conserved 
proinsulin disulfide bonds does not occur “merely by accident”.  The notion of 
spontaneous disulfide bond formation is too simplistic for a compartment as 
complex as the lumen of the endoplasmic reticulum.  I have found that, in 
pancreatic beta cells, specialized ER oxidoreductases both promote, and retard, 
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proinsulin disulfide bond formation and its subsequent trafficking through the 
secretory pathway for insulin production. 
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Figure 4-1. PDI-KD increases secretion of mutant A6/A11 proinsulin. 
Mutant A6/A11 was transfected into 293 cells, and then transfected with 
scrambled or PDI siRNA duplexes. After 48 h post-transfection with either 
scrambled (light bars) or PDI siRNA duplexes (dark bars), the media bathing 293 
cells was changed and fresh media collected between 48 - 72 h.  At that time the 
cells were lysed and proinsulin in both cell lysates and media was measured by 
RIA. For purposes of quantification, the amount of proinsulin recovered in the 
media was divided by the amount recovered in the cells. The control value was 
arbitrarily set to one. (See Chapter 3 Methods for more detail).  
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